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 In chronic lymphocytic leukemia (CLL), one of the best predictors of outcome is 
the somatic mutation status of the immunoglobulin heavy chain variable region (IGHV) 
genes.  Patients whose CLL cells have unmutated IGHV genes have a median survival 
of 8 years; those with mutated IGHV genes have a median survival of 25 years. To 
identify new prognostic biomarkers and molecular targets for therapy in untreated CLL 
patients, we reanalyzed the raw data from four published gene expression profiling 
microarray studies. Of 88 candidate biomarkers associated with IGHV somatic mutation 
status, we identified LDOC1 (Leucine Zipper, Down-regulated in Cancer 1), as one of 
the most significantly differentially expressed genes that distinguished mutated from 
unmutated CLL cases.   
 
 LDOC1 is a putative transcription factor of unknown function in B-cell 
development and CLL pathophysiology. Using a highly sensitive quantitative RT-PCR 
(QRT-PCR) assay, we confirmed that LDOC1 mRNA was dramatically down-regulated 
in mutated compared to unmutated CLL cases. Expression of LDOC1 mRNA was also 
 vii 
strongly associated with other markers of poor prognosis, including ZAP70 protein and 
cytogenetic abnormalities of poor prognosis (deletions of chromosomes 6q21, 11q23, 
and 17p13.1, and trisomy 12). CLL cases positive for LDOC1 mRNA had significantly 
shorter overall survival than negative cases. Moreover, in a multivariate model, LDOC1 
mRNA expression predicted overall survival better than IGHV mutation status or ZAP70 
protein, among the best markers of prognosis in CLL. We also discovered LDOC1S, a 
new LDOC1 splice variant. Using isoform-specific QRT-PCR assays that we developed, 
we found that both isoforms were expressed in normal B cells (naïve > memory), 
unmutated CLL cells, and in B-cell non-Hodgkin lymphomas with unmutated IGHV 
genes.   
 
 To investigate pathways in which LDOC1 is involved, we knocked down LDOC1 
in HeLa cells and performed global gene expression profiling. GFI1 (Growth Factor-
Independent 1) emerged as a significantly up-regulated gene in both HeLa cells and 
CLL cells that expressed high levels of LDOC1. GFI1 oncoprotein is implicated in 
hematopoietic stem cell maintenance, lymphocyte development, and lymphomagenesis. 
 
 Our findings indicate that LDOC1 mRNA is an excellent biomarker of overall 
survival in CLL, and may contribute to B-cell differentiation and malignant 
transformation. 
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CHAPTER 1.  INTRODUCTION 
 
1.1 Chronic Lymphocytic Leukemia (CLL) 
 
Epidemiology 
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the 
Western hemisphere, and it accounts for one third of all leukemias in the United States.  
According to the American Cancer Society 2010 estimates (American Cancer Society, 
2010;http://www.cancer.org/Cancer/LeukemiaChronicLymphocyticCLL/OverviewGuide/ 
index), each year there are about 14,990 new cases and about 4,390 deaths due to 
CLL. The lifetime risk of developing CLL for an average person is about 1 in 200. CLL 
mainly affects adults of advanced age; the average age at diagnosis is 72 years. It is 
uncommon in individuals younger than 40 years, and very rare in children. It is also 
more common in men than women, for unknown reasons. CLL is more common in 
individuals of European than Asian ancestry. There are no proven environmental risk 
factors for CLL. Family history influences CLL risk, with first degree relatives of CLL 
patients having a 2 to 4-fold increased risk to develop CLL. 
 
Diagnosis 
 In most patients (70-80%), the disease is identified incidentally during a routine 
blood test. The remaining patients present with enlarged lymph nodes or systemic 
symptoms, such as malaise, night sweats and weight loss. The diagnosis is established 
by evaluation of peripheral blood lymphocyte count combined with the characteristic 
immunophenotype (1). In advanced stages of the disease patients show signs of 
impaired function of normal bone marrow elements, such as anemia and susceptibility 
to infections. 
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Prognosis 
The clinical course of CLL is variable and difficult to predict. Some patients live 
for many years without treatment, while others have a short survival even with 
treatment. As a result, a variety of clinical and laboratory parameters have been 
developed to predict prognosis. Clinical staging systems developed by Binet, et al. 
(1981) (2) and Rai et al. (1975) (3) remain among the most useful means to determine 
prognosis.  The Rai staging system, used more commonly in North America than the 
Binet system, measures peripheral blood lymphocyte count, disease spread to lymph 
nodes, spleen or liver, and hemoglobin levels and platelet counts. Rai stages advance 
from Stage 0 (increased lymphocyte number only) to stage I (lymph node involvement), 
or stage II (enlargement of spleen or liver and/or lymph nodes), stage III (anemia), and 
stage IV (reduced platelet count). Physicians wait to initiate treatment until patients 
reach advanced stages and develop symptomatic disease. While these staging systems 
are useful to make therapeutic decisions, they are unable to predict long-term survival 
with high precision, especially for patients with early stage disease. A variety of serum 
markers have also been used to predict prognosis in early stage disease, and include 
β2 microglobulin, lactate dehydrogenase, soluble CD23, and serum thymidine kinase. 
 
One of the best predictors of outcome is the somatic mutation status of the 
immunoglobulin heavy chain variable region (IGHV) genes. Patients whose CLL cells 
have unmutated IGHV genes, about 40% of patients, have a median survival of 8 years; 
patients whose CLL cells have mutated IGHV genes, about 60% of patients, have a 
median survival of 25 years (4). Although the somatic mutation status is highly 
associated with prognosis, it has been shown recently that the use of particular heavy 
chain variable region genes, such as VH3-21, is associated with a poor prognosis, 
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regardless of somatic mutation status (5, 6). Thus, the relationship between somatic 
mutation status and prognosis is not absolute. 
 
Chromosomal abnormalities, predominantly gains and deletions (del), are strong 
independent predictors of prognosis in CLL. The most common abnormality is 
del(13)(q14.3), followed by del(11)(q22.3), trisomy 12, del(6)(6q21-q23), and 
del(17)(p13.1). In clinical practice these abnormalities are usually assessed using a 
panel of fluorescence in situ hybridization (FISH) probes (7-9).  As the sole abnormality, 
del(13)(q14.3) is associated with a good prognosis. In contrast, del(6)(q21-q23), 
del(11)(q22.3), del(17)(p13.1), del(13)(q14.3) with other abnormalities, and trisomy 12, 
are associated with more rapid disease progression and inferior survival. The 
abnormalities del(17)(p13.1), the site of the TP53 gene, and del(11)(q22.3), the site of 
the ATM gene, are the most important independent cytogenetic markers of poor 
prognosis. Deletion of (17)(p13.1) is associated with resistance to therapy with purine 
analogs, such as fludarabine, and short survival (10-12). 
 
Gene expression profiling studies have demonstrated that the majority of 
unmutated CLL cases express ZAP70 mRNA (13). Subsequently, others showed that 
expression of ZAP70 protein correlates with mutation status and clinical outcome (14, 
15). Recent studies suggest that ZAP70 protein expression, usually measured by flow 
cytometry, may be a better predictor of time-to-treatment than somatic mutation status 
(16, 17). However, standardization of ZAP70 protein measurement has remained 
challenging for many clinical laboratories, which has limited its use as a routine 
diagnostic test. 
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 A robust biomarker of prognosis that is easily standardized between laboratories 
would have a major clinical impact for CLL patients. 
 
Treatment 
Currently the most effective therapy for CLL is combination 
chemoimmunotherapy with fludarabine (a purine analog that inhibits repair of DNA 
damage), cyclophosphamide (a DNA damaging agent), and Rituximab (a monoclonal 
antibody directed against CD20, a protein on the surface of mature B cells), i.e., FCR 
(Fludarabine-Cyclophosphamide-Rituximab). These agents act synergistically to 
enhance apoptosis of the CLL cells (18). The FCR regimen is the most successful 
combination therapy developed to date, and provides a 6 year survival rate of 77% (18). 
Despite this promising initial response, about one-half of patients treated with frontline 
FCR develop relapse within 3 years of treatment, which is often resistant to further FCR 
therapy. Thus, alternative specific and effective therapy options are needed to treat CLL 
patients.  
 
 
1.2 Emergence of LDOC1 as a potential biomarker 
 
To identify new prognostic biomarkers and molecular targets for therapy in 
untreated patients with CLL, we began this study by reanalyzing the raw data from four 
published gene expression profiling microarray studies (14, 19-21). Of 88 candidate 
biomarkers of IGHV somatic mutation status, we were able to confirm expression of 37 
using a highly sensitive quantitative real-time polymerase chain reaction assay 
performed on microfluidics cards (MF-QRT-PCR) (22). Of these candidate biomarkers, 
the gene LDOC1 (Leucine zipper Down-regulated in Cancer) was one of the most 
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significantly differentially expressed gene that distinguished mutated from unmutated 
CLL cases. (“Mutated” or “unmutated” CLL refers to patients whose CLL cells have 
somatically mutated or unmutated IGHV genes, respectively.) Since unmutated CLL is 
strongly associated with poor prognosis and LDOC1 mRNA is highly upregulated in this 
group of patients, we hypothesized that LDOC1 might not only serve as a promising 
biomarker of prognosis, but might also contribute to CLL pathogenesis and serve as a 
novel candidate molecule for targeted therapies in cancers where it is expressed 
abundantly. 
 
Schema of selection of LDOC1 as a candidate biomarker 
 
 
 
 
36 genes significant 
Screening of CLL literature for microarray studies for genes 
distinguishing unmutated from mutated CLL  
LDOC1 most significant 
 high in unmutated CLL,   low in  mutated CLL 
Evaluation of 88 genes in  
49 untreated CLL patients  
(MF-QRT-PCR) 
 6 
1.4 LDOC1 
 
The LDOC1 gene, located on chromosome Xq27, encodes a 17 kDa protein 
about which very little is known. A leucine zipper motif in the N-terminal region is 
followed by a short proline-rich region, which contains an SH3-binding consensus 
sequence, and then an acidic region in the C-terminus (23). Because leucine zipper and 
SH3-binding motifs mediate protein-protein interactions, LDOC1 protein may regulate 
transcription by homodimerization or heterodimerization with other transcription factors 
through its leucine zipper domain. LDOC1 also may participate in cell signaling by 
providing a binding surface for signaling cascade proteins within its SH3 domain.  
Others have assessed LDOC1 mRNA expression in a wide range of normal tissues and 
in carcinoma cell lines (23). LDOC1 mRNA is expressed ubiquitously in normal tissues, 
although at relatively low levels in leukocytes, liver, and placenta compared with other 
tissues. In tumor cell lines, LDOC1 mRNA is expressed in most breast cancer cell lines, 
but rarely in pancreatic or gastric carcinoma cell lines. Because LDOC1 mRNA is 
expressed in many normal tissues, but is not expressed in most pancreatic and gastric 
carcinoma cell lines, Nagasaki and colleagues have hypothesized that LDOC1 is a 
tumor suppressor gene. Ectopic LDOC1 expression is reported to inhibit NF-kB 
activation in cell lines (24). Others have reported that LDOC1 induces apoptosis in 
Jurkat lymphoma and K562 leukemia cell lines, but not in HeLa cervical carcinoma cells 
(25). Based on these findings, it has been suggested that LDOC1 may have pro-
apoptotic and anti-proliferative effects.  The biologic functions of LDOC1 in normal B-
cell development and the pathophysiology of CLL are unknown. 
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1.5 Overview of Dissertation 
 
LDOC1 is a novel gene and a putative transcription factor. It has emerged as 
one of the most significantly differentially expressed genes in CLL prognostic subtypes: 
LDOC1 mRNA expression is dramatically reduced in CLL cases with somatically 
mutated IGHV genes (associated with a good prognosis) compared to CLL cases with 
somatically unmutated IGHV genes (associated with a poor prognosis) (22). Because 
robust biomarkers of prognosis in CLL are needed, we extended our study to determine 
the value of LDOC1 mRNA expression as a novel clinical biomarker of prognosis.  
Because it is highly expressed in unmutated CLL cases, it also has the potential to 
serve as a candidate molecule for targeted therapies. 
 
The studies presented in this dissertation had four goals. Our first goal was to 
determine if LDOC1 mRNA expression could serve as a clinically useful biomarker of 
prognosis. For this, we evaluated LDOC1 mRNA expression in a large cohort of CLL 
patients to assess its differential expression and correlation with overall survival. As part 
of this evaluation, we also correlated LDOC1 mRNA expression with other known 
prognostic parameters in CLL including IGVH somatic mutation status, cytogenetic 
abnormalities, and ZAP70 expression. Our data suggest that LDOC1 mRNA expression 
has prognostic significance in CLL (26). Our second goal was to investigate changes in 
LDOC1 mRNA levels in normal peripheral blood B cells at different stages of 
development and differentiation, as well as in primary malignant B cells from a variety of 
different lymphoma subtypes. This might provide insights into the possible contributions 
of LDOC1 in physiologic and pathologic changes in B cells. Our findings suggest that its 
dysregulation may contribute to the pathophysiology of CLL and other B-cell 
malignancies (26). It may also play a role in normal B cell development. Our third goal 
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was to gain insight into the biologic pathways in which LDOC1 is involved. To achieve 
this goal, we used siRNAs to reduce LDOC1 protein in HeLa cervical carcinoma cells, 
which abundantly express the protein compared to other solid tumors and hematologic 
malignancies that we have screened. We acquired the RNA and evaluated it for 
changes in 47,000 transcripts in LDOC1-reduced cells relative to the cells containing 
unaltered LDOC1 protein. We found that LDOC1 protein is involved in key signaling 
pathways in HeLa cells including cellular function and maintenance, cell cycle, cellular 
growth and differentiation, cell death, DNA replication and cancer. Our fourth and final 
goal was to validate key genes in these pathways in CLL patient samples using a highly 
sensitive QRT-PCR method. We looked for genes whose expression was concordant 
with respect to LDOC1 expression in transfected HeLa cells and CLL samples, 
suggesting that they might be involved in overlapping biologic pathways in the different 
cell types. We identified the gene, GFI1, whose expression was decreased in HeLa 
cells in which LDOC1 protein had been knocked down, and also in mutated CLL cells, 
which express little or no LDOC1. GFI1 has been implicated in the development and 
function of hematopoietic stem cells, normal lymphoid development and differentiation, 
and lymphomagenesis. 
 
 In summary, we have shown that LDOC1 mRNA expression is a promising 
novel biomarker of survival in untreated CLL patients. Correlative gene expression 
profiling studies in transfected HeLa cells and CLL samples suggest that LDOC1 might 
participate in a common pathway with GFI1, and contribute to CLL pathogenesis. 
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CHAPTER 2.   MATERIALS AND METHODS 
 
2.1 Collection of patient and healthy donor samples 
 
Peripheral blood samples were collected from 131 previously untreated CLL 
patients and six healthy volunteers at The University of Texas M.D. Anderson Cancer 
Center after informed consent was obtained. The study was approved by the 
Institutional Review Board and conducted according to the principles expressed in the 
Declaration of Helsinki.  Normal CD19+ peripheral blood B cells (NBC) and CLL cells 
were purified by negative selection using immunomagnetic beads, and the samples 
processed as described previously (27). In addition, we enriched NBC from healthy 
donors for naïve or memory B cells using a CD27 antibody column, according to the 
manufacturer’s instructions (Miltenyi Biotec, Inc., Auburn, CA). In peripheral blood, 
antigen-naïve B cells (CD27 ) constitute about 60% of the B cells and antigen-
experienced memory B cells (CD27+) about 40% (28). We confirmed the purity of all 
cell preparations by flow cytometry. 
 
Primary lymphoma samples were obtained from either lymph node biopsy 
specimens from patients with follicular lymphoma (two patients) or from the peripheral 
blood of patients in leukemic phase of lymphomas (one patient with follicular lymphoma, 
four patients with mantle cell lymphoma, two patients with splenic marginal zone 
lymphoma, and one patient with marginal zone lymphoma). CD19+ B cells were purified 
as described above (27).  We ensured, by flow cytometry, that each sample contained 
at least 95% CD19+ B cells. 
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2.2 Cell lines  
 
The Epstein-Barr virus-negative Burkitt lymphoma cell line, GA-10, and the T-
cell lymphoblastic lymphoma cell line, Jurkat, were maintained in RPMI medium 
(Mediatech, Inc., Manassas, VA); the breast carcinoma cell line, MCF-7, and the 
cervical carcinoma cell line, HeLa, were maintained in DMEM (Mediatech).  Both media 
were supplemented with 10% fetal bovine serum (Sigma, St. Louis, MO) and 2 mM L-
glutamine (Mediatech). We harvested the lymphoma cell lines during the exponential 
phase of growth; the confluence of the MCF-7 and HeLa cells at the time of harvest is 
indicated in the text. 
 
2.3 Nucleic Acid Preparation 
 
 Total RNA was extracted using guanidine isothiocyanate/phenol-chloroform 
extraction with TRIzol reagent (Life Technologies, Inc., Gaithersburg, MD) according to 
the manufacturer’s instructions. The quality of the RNA was assessed by agarose gel 
electrophoresis.  For all subsequent PCR assays, total RNA was reverse transcribed 
using random hexamers and a First-Strand cDNA synthesis kit (GE Healthcare, 
Piscataway, NJ). We used a final concentration of 10 ng/µL of reverse-transcribed 
product.  For microarray gene expression profiling experiments, total RNA was further 
purified with RNeasy MinElute Cleanup Kit (Qiagen, Valencia, CA). DNA was extracted 
using a Qiagen DNeasy kit (Qiagen Sciences, Maryland) according to the 
manufacturer’s instructions. The quality of the RNA used for gene expression profiling 
microarray studies was assessed by Bioanalyzer analysis in the Genomics Core Facility 
and met their quality control standards.  
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2.4 Evaluation of the IGHV somatic mutation status 
 
For our studies, we obtained the somatic mutation status of the IGHV genes for 
a total of 130 CLL and 10 primary B-cell lymphoma samples. We assessed the somatic 
mutation status of the IGHV genes in 66 CLL and 10 primary B-cell lymphoma samples 
as described previously, with minor modifications (27). Patient DNA sequences were 
aligned to the germline DNA sequences in VBASE II and the degree of IGHV somatic 
mutation was determined (29). For 54 patients, analysis of the somatic mutation status 
was performed in the clinical Molecular Diagnostics Laboratory at our institution and 
obtained by review of the medical records. For 10 patients, the somatic mutation status 
was performed by the Chronic Lymphocytic Leukemia Research Consortium laboratory, 
and the results were obtained from the CLL Database of the Protocol Data 
Management System (CLL-PDMS), which is maintained by our collaborator, Dr. Michael 
Keating. The IGHV somatic mutation status was designated as “unmutated” if there 
were fewer than 2%, or as “mutated” if there were 2% or more mutations compared to 
the germline sequences (30). 
 
2.5 Assessment of ZAP70 protein expression  
 
Expression of ZAP70 protein was assessed by either immunohistochemistry or 
flow cytometry.  Immunohistochemical staining was performed using routinely fixed and 
processed paraffin-embedded tissue sections of bone marrow core biopsy and/or clot 
specimens and a specific monoclonal antibody (Upstate Cell Signaling Systems, Lake 
Placid, NY), as described previously (17, 31). Immunohistochemical stains for ZAP70 
protein were scored as either positive or negative by hematopathologists, and the 
results obtained from the patients’ medical records. The flow cytometry assay for 
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ZAP70 protein expression was performed by the Chronic Lymphocytic Leukemia 
Research Consortium laboratory, as described previously (16). The results were 
obtained from the CLL Database of the Protocol Data Management System (CLL-
PDMS), which is maintained by our collaborator, Dr. Michael Keating. 
 
2.6 LDOC1 mRNA expression by reverse-transcriptase polymerase chain 
reaction assay 
 
We used two primer pairs to amplify either the entire coding region (primer pair 
AB) or the mRNA (primer pair AC) of the LDOC1 gene in a reverse-transcriptase 
polymerase chain reaction (RT-PCR) assay. Primer pair AB, designed to amplify the 
entire LDOC1 coding region, yields a product of 464 bp, as reported by others (23).  We 
designed a second reverse primer, C (5'-AGCAGGTAACTGGAGCGCTA-3'), which 
binds within the 3' untranslated region (3' UTR). Primer pair AC was expected to yield a 
product of 649 bp.  The cDNA (80 ng) was amplified in the presence of primers, 
reaction buffer, deoxynucleotide triphosphates (2.5 M each), and HotStar Taq DNA 
polymerase. Following incubation at 95 C for 10 minutes, the cDNA was amplified for 
35 cycles of at 95 C for 15 seconds, 55 C for 30 seconds, and 72 C for 45 seconds, 
followed by a final extension at 72 C for 7 min. The amplified products were separated 
by agarose gel electrophoresis, extracted from the gel, and purified.  The sequence of 
the PCR products was determined directly using the forward and reverse PCR primers, 
and an ABI 3700 or 3730 DNA Analyzer (Applied Biosystems, Foster City, CA). The 
sequences were aligned to the LDOC1 reference sequence (GenBank RefSeq 
NM_012317) using NCBI SPLIGN algorithm and LaserGene v7.2 software (DNASTAR).  
The cDNA amount and integrity were ensured by amplifying the housekeeping gene, 
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beta-actin, using forward (5'-GATCATGTTTGAGACCTTCAAC-3') and reverse (5'-
TCTTTGCGGATGTCCACGTC-3') primers (27). The RT-PCR conditions were identical 
to those used for the LDOC1 RT-PCR assay; and the reactions were run 
simultaneously with the reactions amplifying LDOC1. 
 
2.7 Total LDOC1 mRNA expression determined by quantitative real-time 
polymerase chain reaction assays 
 
 
 We used two different quantitative real-time polymerase chain reaction assays 
(QRT-PCR) to detect total LDOC1 mRNA expression: 1) a high-throughput assay using 
microfluidics cards (MF-QRT-PCR) and 2) a standard QRT-PCR assay. The LDOC1 
TaqMan probe and primer sets were identical in both assays. The primers and probe 
bind to 3' UTR sequences that are present both in wild-type LDOC1 and its splice 
variant, LDOC1S (TaqMan Assay, Hs00273392_s1, Applied Biosystems). In the MF-
QRT-PCR assay, custom microfluidics cards were printed with primers and probes 
corresponding to 88 candidate mRNA biomarkers of IGHV somatic mutation status, 
including LDOC1 and ZAP70. We used five endogenous control genes (18S rRNA, 
GAPD, PGK1, GUSB, and ECE-1), and performed the MF-QRT-PCR assays, as 
described previously (22). The expression of each gene was assessed in duplicate. 
 
In the standard QRT-PCR assay, the PCR reactions for LDOC1 mRNA were 
carried out in 25 L reaction volumes that contained 5 L cDNA at a concentration of 
10ng/ L.  In addition, 1X TaqMan Universal PCR Master Mix without AmpErase UNG, 
unlabeled LDOC1-specific PCR primers, and a 6-carboxy fluorescein (FAM)–labeled 
TaqMan minor groove binder (MGB) probe were added. In all experiments, we amplified 
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of 18S ribosomal RNA (rRNA) as an internal control to normalize the LDOC1 values.  
The probe for 18S rRNA is labeled with the VIC reporter dye. The PCR reaction 
conditions were as follows. After incubation at 95°C for 10 minutes, the cDNA was 
amplified for 45 cycles of denaturation at 95°C for 15 seconds and combined 
annealing/extension at 60°C for 1 minute. Each sample was analyzed in triplicate in a 
PRISM 7000 Sequence Detector (Applied Biosystems). We used the 7500 Fast System 
version 1.4.0 software (Applied Biosystems) to analyze the fluorescence emission data 
following QRT-PCR. The threshold cycle (Ct) values of each sample were exported to 
Microsoft Excel for further analysis.  The Ct value represents the cycle number at which 
fluorescence originating from each sample passes a predetermined single threshold.  
The ΔCt for LDOC1 mRNA was obtained by subtracting the Ct value of 18S rRNA from 
the Ct value of LDOC1 mRNA for each sample. The LDOC1 mRNA expression levels in 
test samples are presented as relative quantities (RQ), computed as:  2-ΔΔCt = 2-(ΔCt test - 
ΔCt calibrator), where the calibrator represents an equal mixture of cDNA obtained from GA-
10 and Jurkat cells. 
 
2.8 Expression of LDOC1 mRNA isoforms by isoform-specific QRT-PCR 
assays 
 
 
In order to assess the contribution of each of the LDOC1 mRNA isoforms to the 
total LDOC1 mRNA expression, we designed two specific TaqMan assays that 
distinguish between the isoforms.We used Primer Express software (Applied 
Biosystems) to search for and select the primer and probe combinations from a ranked 
list generated by the software. In the TaqMan assay that specifically recognizes the 
wild-type LDOC1 sequences (Custom LDwt1, part number 4331348), the 5’ primer 
anneals to sequences 5'–TGGTGCCCTACATCGAGATG-3', the 3' primer anneals to 
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sequences 5’-CGAGGAAGGCCCGGTAA-3', and the TaqMan probe anneals to 
sequences 5'–ATAGCCCCATCCTAGGTG-3'. In the TaqMan Assay that specifically 
detects the splice variant LDOC1S transcript, the TaqMan probe (Custom LDsv1, part 
number 4331348) targets the junction sequence located between nucleotides 183 to 
233 and 718 to 785. The 5' primer anneals to sequences 5'-
TTCCAAGCACTTCCGAGTGA-3', the 3’ primer anneals to sequences 5'-
ATGGAACAGCTGCGGCTG-3', and the TaqMan probe anneals to sequences 5'-
CTATTCCTGGCGCAGCAG-3'. Assays were ordered on the Applied Biosystems 
Custom TaqMan Assay Design Tool (https://www5.appliedbiosystems.com/tools/cadt/). 
 
2.9 Detection of genomic gains and losses by single nucleotide polymorphism 
(SNP) genotyping 
 
Genomic DNA was extracted from purified CLL cells, as described above.  
Genotypic analysis was performed on DNA obtained from 100 CLL samples using the 
Illumina HumanHap610 chip, according to the manufacturer’s instructions, in 
collaboration with Dr. Bogdan Czerniak, Department of Anatomic Pathology.  
Background subtraction and normalization were performed using the default settings in 
the Illumina BeadStudio software.  Log R ratios (LRR), B allele frequencies (BAF), and 
genotype calls were exported from BeadStudio for analysis in the R statistical 
programming environment (version 2.8.1). Segments of constant copy number in the 
LRR data were identified by applying the circular binary segmentation (CBS) algorithm, 
as implemented in the DNAcopy package (version 1.16.0) (32). Segments with mean 
LRR < 0 .15 and two bands in the BAF plot were called “deleted”; segments with mean 
LRR > 0.15 and four bands in the BAF plot were called “gained”. The data were 
evaluated to detect common abnormalities associated with CLL, i.e., deletions of 6q21, 
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11q22.3, 13q14.3, and 17p13.1, and trisomy 12; we also evaluated the DNA for gains or 
deletions of LDOC1. The data were analyzed by our collaborator, Dr. Kevin Coombes, 
Department of Bioinformatics and Computational Biology. Following analysis, the 
genomic changes were visually inspected to ensure the accuracy of the calls made by 
the computer algorithm were correct. 
 
2.10 Statistical analysis 
 
Comparisons of LDOC1 positive and negative patient groups were performed 
using two different tests (Table 1). For discrete variables (all parameters except age), 
we used the two-sided Fisher’s exact test to compare the means of the two groups. For 
the continuous variable (age), we used an unpaired two-sample t-test assuming 
unequal variances to compare the mean. Time-to-event (survival) analysis was 
performed using Cox proportional hazards models. Significance was assessed using 
the log-rank (score) test. To assess multivariate models, we used a forward-backward 
stepwise algorithm to eliminate redundant factors and optimize the Akaike Information 
Criterion (AIC) (33).  All computations were performed using either the survival package 
(version 2.35-8) in the R statistical programming environment (version 2.11.1) 
(performed by Dr. Kevin Coombes) or STATA Statistics/Data Analysis software version 
10.0 (performed by Hatice Duzkale). Multivariate survival analysis and analysis of the 
88 candidate biomarkers of prognosis by MF-QRT-PCR were performed in collaboration 
with Dr. Kevin Coombes. 
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2.11 LDOC1 protein knock-down in HeLa cells 
 
HeLa cells were obtained from ATCC, and were at passage 2 since their receipt 
from the ATCC at the beginning of the experiments. The cells were thawed and 
passaged twice before seeding for the experiment. When they reached approximately 
90% confluence they were harvested by trypsinization and counted; the cell viability, 
assessed by trypan blue dye exclusion, was greater than 90%. The cells were seeded 
at 1.5 x 105 cells per well in 2 mL complete DMEM medium (Mediatech), into 6-well 
plates. 
 
Twenty four hours after seeding, the cultures were inspected using an inverted 
light microscope to ensure that the cells had reached 40-50% confluence and were 
evenly distributed. For transfection, the complete medium containing 10% FBS was 
replaced with DMEM medium containing 1% FBS, according to the manufacturer’s 
instructions (Lipofectamine 2000, Invitrogen, Carlsbad, CA). Knock-down of LDOC1 and 
LDOC1S mRNAs was performed using siRNA pools that contain four different siRNAs, 
all of which hybridize to the amino acid coding region (ON-TARGETplus SMARTpool 
siRNA pool; Thermo Scientific, Lafayette, CO). One of these siRNAs also recognizes 
the splice variant LDOC1S. For the negative controls, we used either a single non-
targeting siRNA (ON-TARGETplus Non-targeting siRNA #1 for the time-course 
optimization experiments) or a pool of four non-targeting siRNAs (ON-TARGETplus 
Non-targeting Pool for the global gene expression profiling microarray experiments).  
The non-targeting siRNAs do not hybridize to any region in the human genome, and 
control for sequence-nonspecific silencing effects during siRNA transfection experiment.  
Water was used for the “mock” transfection control. The siRNAs were added to each 
culture at a final concentration of 100 nM. The cells were incubated with the siRNAs in 
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the presence of 1% FBS for 24 hours at 37 C with 5% CO2. After this incubation, FBS 
was added to achieve a final concentration of 10% FBS. For the optimization 
experiments, the cells were continuously incubated with the siRNAs until they were 
harvested. For the gene expression profiling studies, the cells were incubated with the 
siRNAs for 56 hours, the medium replaced with complete medium containing 10% FBS, 
and then harvested at 93 hours post-transfection. 
 
In the same experiment we also assessed the transfection efficiency using 
fluorescent-labeled control siRNAs (siGLO Transfection indicator-Red; Thermo 
Scientific). The transfection efficiency was determined using fluorescence microscopy 
by counting three different fields at 40x magnification, and calculated as:  Efficiency = 
mean number of the red-fluorescing cells / (mean number of the total fluorescent + non-
fluorescent cells). 
 
2. 12 Cell cycle analysis 
 
After harvesting, cells were washed with cold PBS and fixed with cold ethanol 
(70%). They were incubated at 4oC at least for 24 hours, and stained with propidium 
iodide (PI).  A flow cytometer was used to measure DNA content of the cells. Cell cycle 
analysis was done using software MultiCycle (Phoenix Flow Systems, Inc., San Diego, 
CA). 
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2. 13 Evaluation of LDOC1 protein expression K\knock-down by Western blot 
 
 Whole cell lysates were prepared from freshly isolated cultured HeLa cells.  
After removing the medium, the cells were washed, detached with trypsin, transferred to 
cold 15 mL culture tubes, and spun at 1500 rpm for 5 minutes at 4oC in a refrigerated 
centrifuge. After removing the supernatant, the cell pellets were stored at -80oC for a 
minimum of 24 hours to denature the cellular proteins. The pelleted cells were lysed on 
ice in lysis buffer (25 mM Hepes, pH 7.7, 400 mM sodium chloride, 1.5 mM magnesium 
chloride, 2 mm ethylenedinitrilotetraacetic acid (EDTA), 0.5% Triton X-100).  
Immediately before use, the reducing agent 3 mM dithiothreitol (DTT), 20 mM beta-
glycerophosphate, 2 mm sodium orthovanadate (Na3VO3), 5 mM sodium fluoride, 25 
mM para-nitrophenyl-phosphate disodium (PNPP), 0.1 mM phenyl methyl sulfonyl 
fluoride (PMSF), and complete protease inhibitor cocktail (Roche, Indianapolis, IN) were 
added to the lysis buffer. The lysates were homogenized by sonication, placed on ice 
for 30 minutes, and spun at 4oC in a refrigerated centrifuge to remove cellular debris.  
The protein concentration was measured by Bradford assay.  Total protein (100 µg) was 
heat denatured for 3 minutes in sample buffer (50 mM Tris-HCl (pH 6.8), 10% glycerol, 
2% SDS, 0.025% bromophenol blue, 2.5% ß-mercaptoethanol), separated by 15% Tris-
HCl SDS polyacrylamide gel electrophoresis, and transferred to a polyvinylidene 
fluoride (PVDF) membrane.  The membrane was blocked with 3% non-fat milk in PBS-T 
buffer (PBS with 0.05% Tween 20) and incubated overnight at 4OC with either affinity-
purified polyclonal mouse anti-human LDOC1 antibody (dilution 1:500; Abnova, Taiwan) 
or monoclonal mouse anti-human beta-actin antibody conjugated to horse-radish-
peroxidase (HRP) (dilution 1:25,000; Sigma, St. Louis Missouri). All antibodies were 
diluted in 3% milk with PBS-T. The membranes were washed twice with PBS-T for 10 
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min, once with PBS for 10 min, and then once with ddH2O for 30 min. To detect LDOC1, 
the membranes were incubated for a minimum of 60 minutes at room temperature with 
anti-mouse secondary antibody conjugated to HRP (GE Healthcare, United Kingdom) 
and washed, as described above. After exposure to chemiluminescent substrate for 1 
minute, the peroxidase reaction was detected using the Enhanced Chemiluminescent-
plus (ECL-plus, GE Healthcare) system for LDOC1 and the ECL system (GE 
Healthcare) for beta-actin. 
 
2.14 Global gene expression profiling 
 
We used GeneChip Human Genome U133 Plus 2.0 arrays (Affymetrix, Santa 
Clara, CA) for the 3’ in vitro transcription (IVT) expression analysis. This chip contains 
more than 54,000 probe sets that interrogate 47,000 transcripts from approximately 
38,500 well-characterized human genes. The hybridizations were performed in triplicate 
according to the manufacturer’s instructions. The experiment was performed using six 
chips, three chips for each of two conditions: LDOC1 siRNA-treated HeLa cells (LD 
group) and non-targeting siRNA-treated HeLa cells (NT group).  Briefly, total RNA (100 
ng per chip) was reverse transcribed using a T7 oligo(dT) primer to synthesize cDNA 
that contains the T7 promoter sequence. This first strand cDNA was then converted to 
double-stranded DNA by DNA polymerase in the presence of RNase H, which 
simultaneously degrades the RNA during the reaction. The in vitro transcription reaction 
was performed in the presence of T7 RNA polymerase and biotinylated ribonucleotide 
analogues. Subsequently, the amplified RNA (cRNA) was purified to remove 
unincorporated nucleotide triphosphates (NTP), enzymes, salts and inorganic 
phosphate to improve the stability of the biotin-modified cRNA. The expected size of the 
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cRNA is between 250-5500 nucleotides (nt), with a peak size of 600-1200 nt. The cRNA 
was then fragmented to obtain 35-200 nt fragments, with a peak size ranging from 100-
120 nt. The fragments were then hybridized to the chips at 45oC for 16 hours. The chips 
were then scanned with a GeneArray Scanner (Hewlett-Packard, Palo Alto, CA). The 
entire hybridization procedure was performed in the institutional Core Facility. 
 
2.15 Statistical analysis of gene expression profiling microarray data 
 
All data pre-processing and statistical analyses were performed in R, a free 
software environment for statistical computing and graphics (http://www.r-project.org/).  
As part of standard quality control (QC) analysis, the .CEL files were quantified using 
the MAS5 algorithm. The data quality was examined by preparing RNA degradation 
plots, Bland-Altman (M-versus-A) pairwise plots, density plots, and box plots. Then, the 
expression levels were quantified using the method “Robust Multiarray Analysis (RMA)”.  
A two-sample t-test was performed to identify differentially expressed genes between 
LD and NT groups. To account for multiple testing, a beta-uniform mixture (BUM) model 
was applied to estimate false discovery rate (FDR). 
 
In order to identify genes that were coordinately expressed in HeLa and CLL 
cells, we compared the data obtained from the HeLa knock-down experiments with 
gene expression profiling data previously acquired on 30 CLL samples in our laboratory 
(34). These CLL samples had been hybridized to the Affymetrix U133A 2.0 gene 
expression microarrays, which contain 22,283 probe sets. The array assesses the 
expression level of 18,400 transcripts and variants, including 14,500 well-characterized 
human genes. Data were processed using RMA, and two group comparisons between 
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LDOC1-high and LDOC1-low samples were performed using two-sample t-tests. The 
microarray gene expression analyses were performed in collaboration with Dr. Kevin 
Coombes. 
 
2.16 Pathway analysis  
 
Pathway analysis of differentially expressed genes was performed using the 
Ingenuity Pathway Analysis (IPA), a web-based algorithm (Ingenuity® Systems, IPA 
version 9.0, www.ingenuity.com) (35). For this analysis, the mean gene expression 
values were first base-two log transformed. To determine fold changes, the ratio of the 
LD/NT groups were calculated using Excel. Based on their p values, the ratios of the 
most significantly differentially expressed 107 genes were uploaded into the IPA 
algorithm. A core analysis was performed using a 0.5 fold change in ratio as the cut-off, 
querying only the direct interactions. The IPA algorithm uses literature-curated and 
database-originated a priori knowledge (Ingenuity Knowledge Base) and builds 
networks using those interactions as scaffolds, filling in with the gene list uploaded by 
the user. 
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CHAPTER 3. LDOC1 IS DIFFERENTIALLY EXPRESSED IN CLL PROGNOSTIC 
SUBTYPES AND PREDICTS OVERALL SURVIVAL IN UNTREATED PATIENTS 
 
3.1 Introduction 
 
In an earlier study performed to identify candidate biomarkers associated with IGHV 
somatic mutation status in 49 previously untreated CLL patients, our group identified 
LDOC1 as one of the genes that was differentially expressed with strong statistical 
significance between mutated and unmutated cases (22). We have expanded this 
analysis to a total of 131 samples obtained from previously untreated CLL patients and 
evaluated the potential of LDOC1 mRNA as biomarker of prognosis. Our analyses 
included correlations with known standard clinical and laboratory markers of prognosis, 
and univariate and multivariate survival analyses. 
 
3.2 Results 
 
3.2.1 LDOC1 mRNA expression is strongly associated with known markers of 
 poor prognosis 
 
We expanded our previous analysis of 49 samples (22) to a total of 131 samples 
obtained from untreated CLL patients. We found that the distribution of LDOC1 
expression was bimodal, with no patients exhibiting CT values between 7 and 8 cycles 
Figure 1). Thus, we defined samples to be LDOC1-positive if CT  7.5 and LDOC1-
negative if CT > 7.5. 
 
 24 
 
 
 
Figure 1. Histogram of the observed LDOC1 values in normalized cycles 
demonstrates a clear separation of CLL samples. Normalized Ct values of 131 CLL 
samples obtained by MF-QRT-PCR assay are shown on the X-axis. The red vertical 
line indicates the cut-off point to allocate LDOC1 mRNA expression into positive (to the 
left of the red line) or negative (to the right of the red line) groups. The figure contains 
continuous (blue line) and discrete (histogram) approximations of the "probability 
density" function. The area of each bar represents the percentage of patient samples 
that have values in the interval represented by the x-axis values. 
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The patient characteristics in both groups are summarized in Table 1. With 
respect to age, gender, Rai stage, white blood cell count, or serum beta-2 microglobulin 
levels at the time the sample was obtained, there were no statistically significant 
differences between patients whose cells expressed LDOC1 mRNA and those whose 
cells were negative for LDOC1 mRNA. Since we originally identified LDOC1 mRNA as a 
biomarker of IGHV somatic mutation status (22), its expression strongly correlated with 
the somatic mutation status, as expected (Fisher’s exact test; p=2.20 x 10-16). For each 
case, the data for the IGHV somatic mutation status, IGHV family, percent homology 
with the germline sequence, and LDOC1 mRNA expression, as well as ZAP70 protein 
expression and cytogenetic findings, are listed in Supplementary Table 1. 
 
Out of a total of 131 cases, 65 out of 67 mutated cases (97%) were negative for 
LDOC1 mRNA, and 43 out of 63 unmutated cases (68%) were positive for LDOC1 
mRNA; the IGHV somatic mutation status was unavailable for one case (Figure 2A, 
Supplementary Table 1). Equivalently, 43 out of 45 (96%) LDOC1-positive cases were 
unmutated and 65 out of 85 (76%) LDOC1-negative cases were mutated. Thus, 22 
cases (17%) showed discordance between LDOC1 mRNA expression and IGHV 
somatic mutation status; two mutated cases were LDOC1-positive and 20 unmutated 
cases were LDOC1-negative. 
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Table 1.  Clinical and Laboratory Features†, ** 
 All 
Patients 
LDOC1 
positive 
LDOC1 
negative 
p value* (n = 131) (n = 46) (n = 85) 
Age in years     
Median 59 60 59 0.6796 
(range) (27 – 82) (27 – 82) (27 – 81)  
Gender     
Male, n (%) 81 (62%) 27 (59%)  54 (64%) 0.7066 
Female, n (%) 50 (38%) 19 (41%) 31 (36%)  
Rai stage (n = 131) (n = 46) (n = 85)  
0-2, n (%) 102 (78%) 35 (76%) 67 (79%) 0.826 
3-4, n (%) 29 (22%) 11 (24%) 18 (21%)  
WBC count (n = 131) (n = 46) (n = 85)  
 150x109/L, n (%) 118 (90%) 38 (83%) 80 (94%) 0.0621 
> 150x109/L, n (%) 13 (10%) 8 (17%) 5 (6%)  
Serum 2 microglobulin (n = 130) (n = 46) (n = 84)  
< 4, n (%) 98 (75%) 31 (67%) 67 (80%) 0.1384 
 4, n (%) 32 (25%) 15 (33%) 17 (20%)  
IGHV somatic mutation 
status (n = 130) (n = 45) (n = 85)  
Mutated, n (%) 67 (52%) 2 (4%) 65 (76%) 2.20 x 10-16 
Unmutated, n (%) 63 (48%) 43 (96%) 20 (24%)  
ZAP70 protein status (n = 113) (n = 39) (n = 74)  
Positive, n (%) 51 (45%) 30 (77%) 21 (28%) 1.06 x 10-6 
Negative, n (%) 62 (55%) 9 (23%) 53 (72%)  
Cytogenetic changes (n = 100) (n = 39) (n = 61)  
None, n (%) 27 (27%) 14 (36%) 14 (23%)  
isolated del(13q), n (%) 36 (36%) 5 (13%) 30 (49%) 0.0005834 
del(6q), del(11q), del(17p), 
+12, or 
del(13q) with other 
abnormalities, n (%) 
37 (37%) 20 (51%) 17 (28%)  
† Age, Rai stage, WBC count, and serum 2 microglobulin values are reported for the 
time the sample was obtained for LDOC1 mRNA expression; IGHV somatic mutation 
status, ZAP70 protein status, and cytogenetic changes were determined on samples 
obtained before treatment. 
* All p values were calculated using the two sided Fisher’s exact test except for age in 
years, which was calculated using the two-sided t-test. 
** For serum 2 microglobulin and IGHV somatic mutation status, one value was 
unavailable; for ZAP70 protein, 18 values were unavailable, for genomic abnormalities, 
31 values were unavailable. 
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Figure 2 
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Figure 2:  Expression of LDOC1 and ZAP70 mRNAs measured by MF-QRT-PCR 
assay distinguishes between mutated and unmutated cases of CLL.  (A) Dot-plot 
for LDOC1 mRNA expression. For the mutated cases, 65 out of 67 mutated cases 
were unambiguously negative for LDOC1 mRNA (higher CT values) and 2 were 
positive (lower CT values). For the unmutated cases, 43 out of 63 unmutated cases 
were positive for LDOC1 mRNA and 20 were negative.  (B) Dot-plot for ZAP70 mRNA 
expression.  For the unmutated cases, 53 out of 63 unmutated cases were positive for 
ZAP70 mRNA and 10 were negative. Eleven out of 67 mutated cases were positive for 
ZAP70 mRNA and 56 were negative. The CT value considered for threshold = 5.3 
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3.2.2 LDOC1 mRNA expression more strongly predicts IGHV somatic mutation 
 status than does ZAP70 protein expression 
 
Since evaluation of ZAP70 protein expression has been considered a surrogate 
biomarker for IGHV somatic mutation status (36, 37), we evaluated the association 
between IGHV somatic mutation status and ZAP70 protein expression, measured by 
immunohistochemistry or flow cytometry (IHC/Flow). We detected a positive association 
between ZAP70 protein positivity by IHC/Flow and IGHV somatic mutation status 
(Fisher’s exact test; p=1.42 x 10-9). Of the 112 cases for which ZAP70 protein 
expression data were available, 24 (21%) showed discordance between IGHV somatic 
mutation status and ZAP70 protein expression (Table 2), consistent with the results of 
previous studies (14, 16, 17, 31, 36, 37). Eleven out of 59 mutated cases (19%) were 
ZAP70 positive; 13 out of 53 unmutated cases (25%) were ZAP70 negative. Thus, 
LDOC1 mRNA expression was more strongly associated with IGHV somatic mutation 
status than was ZAP70 protein expression. 
 
ZAP70 protein UM M Total 
Positive 40 11 51 
Negative 13 48 61 
Total 53 59 112 
 
Table 2. Correlation of ZAP70 protein expression and IGHV mutation status. Only 
in 112 patients data were available for both ZAP70 protein expression and IGHV 
mutation status. UM, IGHV-unmutated; M, IGHV-mutated 
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3.2.3 LDOC1 mRNA expression is associated with cytogenetic markers of 
prognosis 
 
We found that expression of LDOC1 mRNA correlated with cytogenetic markers 
of prognosis (Table 1, Fisher’s exact test; p= 0.0005834; Supplementary Table 1).  
Cases that were negative for LDOC1 mRNA were more likely to harbor isolated 
deletions in chromosome 13q14.3, a marker of good prognosis, compared to samples 
that were positive for LDOC1 mRNA. In contrast, cases that were positive for LDOC1 
mRNA were more likely to harbor genomic abnormalities associated with poor 
prognosis, i.e., del(6)(q21), del(11)(q22.3), del(17)(p13.1), +12, or with del(13)(q14.3), 
another cytogenetic marker of poor prognosis, than cases that were negative for 
LDOC1 mRNA expression. 
 
3.2.4 Total LDOC1 mRNA expression is a better predictor of overall survival 
 than either IGHV somatic mutation status or ZAP70 protein expression 
 
Since LDOC1 mRNA expression was associated with IGHV somatic mutation 
status and ZAP70 protein expression, both strong predictors of prognosis in CLL 
patients, we sought to determine if LDOC1 mRNA expression could also serve as a 
biomarker of prognosis. Thus, we analyzed the relationship between LDOC1 mRNA 
expression and overall survival. We found that patients whose cells were negative for 
LDOC1 mRNA had a significantly longer median survival than patients whose cells 
were positive, regardless of whether overall survival was measured from the time of 
diagnosis (Figure 3; logrank test, p = 0.009581) or from the time the sample was 
obtained (logrank test, p = 0.02294; data not shown). The median survival for the 
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LDOC1 mRNA negative patients was not reached, whereas the median survival for 
LDOC1 mRNA positive patients was 164 months. 
 
Further, we applied the Akaike Information Criterion (AIC) to a multivariate 
model that incorporated LDOC1 mRNA expression, ZAP70 protein expression, and 
IGHV somatic mutation status. The optimal model retained only LDOC1 mRNA 
expression (AIC = 167.93), eliminating ZAP70 protein expression (AIC = 169.2) and 
mutation status (AIC=171.02). Smaller values of AIC provide better models (33). Thus, 
in this sample set LDOC1 mRNA expression was a better predictor of overall survival 
than either IGHV somatic mutation status or ZAP70 protein expression. (The 
multivariate model was constructed by our collaborator, Dr. Kevin Coombes). 
 
3.3 Summary 
 
We have shown that LDOC1 mRNA expression positively correlates with 
important known biomarkers of poor prognosis, i.e., unmutated IGHV somatic mutation 
status, ZAP70 protein expression, and cytogenetic markers of poor prognosis. Further, 
LDOC1 mRNA expression is associated with shorter overall survival in a univariate 
analysis. Finally, LDOC1 mRNA is an excellent biomarker of prognosis in untreated CLL 
patients, and is a better predictor of overall survival than either IGHV somatic mutation 
status or ZAP70 protein expression, the current gold standard biomarkers of prognosis 
in CLL. 
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Figure 3. LDOC1 mRNA expression predicts overall survival. Overall survival 
was measured from the time of CLL diagnosis. The median survival for LDOC1 mRNA 
positive patients was 164 months (13.7 years); the median survival for the LDOC1 
mRNA negative patients was not reached. 
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CHAPTER 4. LDOC1 IS DIFFERENTIALLY EXPRESSED IN NORMAL PERIPHERAL 
BLOOD B CELL SUBSETS AND IN SUBTYPES OF PRIMARY NON-HODGKIN 
LYMPHOMAS 
 
4.1   Introduction 
 
Little is known about the expression of LDOC1 mRNA in normal B cells (NBC) or 
in lymphoid malignancies other than CLL. To begin to understand its biological role in B 
cell development, differentiation, activation, and transformation we screened a variety of 
normal and malignant B-cell subsets for LDOC1 mRNA expression. We used the RT-
PCR to identify novel mRNA variants and the QRT-PCR to measure the relative 
amounts of the isoforms. During the course of our studies we discovered a new splice 
variant, LDOC1S. 
 
4.2   Results 
 
4.2.1 RT-PCR analysis of LDOC1 mRNA reveals a novel splice variant, LDOC1S 
 
We assessed LDOC1 mRNA expression in NBC, a variety of primary B-cell 
lymphoma samples, and carcinoma cell lines, using two primer pairs, AB and AC 
(Figure 4). Primer pair AB was designed to amplify the entire LDOC1 coding region and 
yield a product of 464 bp (23). The reverse primer, C, in primer pair AC was designed to 
bind within the 3' UTR and yield a product of 649 bp. Using primer pair AB we detected 
strong expression of the expected wild-type 464 bp product in seven unmutated CLL 
cases (CLL 42, 46, 49, 51, 53, 54, 60), two NBC samples (NBC 4, 6), and the MCF-7 
breast carcinoma cell line, which has been shown to express high levels of LDOC1 (23) 
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(Figure 5A and B). We detected faint or no RT-PCR products in seven mutated CLL 
cases (CLL 58, 62, 12, 37, 61, 67, 99), or in the GA-10 Burkitt lymphoma and Jurkat T-
cell lymphoblastic lymphoma cell lines. However, primer pair AC yielded two distinct 
bands in all positive samples, the expected 649 bp product and an unexpected 165 bp 
product. Three out of four additional NBC samples, as well as normal peripheral blood T 
cells and HeLa cervical carcinoma cells were also positive with both primer pairs (data 
not shown). 
 
In a subset of CLL cases that expressed LDOC1 mRNA (CLL 46, 49, 53), we 
determined the sequence of the 464, 165, and 649 bp products.  We also determined 
the sequence of the 464 and 649 base pair products in a subset of NBC cases (NBC 1, 
3, 5). The sequences from the 464 and 649 bp products were identical to the published 
LDOC1 reference sequence (GenBank RefSeq NM_012317). Sequence analysis of the 
165 bp product revealed that it was a splice variant (Figure 4B). The LDOC1 gene is an 
intronless gene that encodes an mRNA of 1376 bp (23). The LDOC1 and LDOC1S 
mRNAs have identical translation start sites, with a sequence similar to that described 
by Kozak (38). The splice variant contains canonical splice donor (AG|GTACGT at 
nucleotide 232) and acceptor sequences (TGTCTTTGTTCCAG|G at nucleotide 704), as 
well as a branch sequence (TTCAT at nucleotide 685) (Alex’s Splice Site Finder, 
version 0.5; NNSplice, version 0.9). Thus, in the splice variant, approximately the first 
third of the amino acid coding region is joined with the 3' UTR at nucleotide 718. After 
one codon (GAA, glutamic acid), the coding sequence is terminated by a stop codon 
(TAG), followed by a 3’UTR that is identical to the wild-type sequence. If translated, the 
165 bp splice variant would produce a truncated protein of 44 amino acids that contains 
the leucine zipper region of the wild-type protein; the proline rich-region (amino acids 
46-65) and the remainder of the coding region would be absent (Figure 4C).
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Figure 4:  Structure of the LDOC1 wild-type and splice variant mRNAs, and 
translated proteins.  (A and B) Structure of the LDOC1 and LDOC1S mRNAs, 
respectively.  The LDOC1 gene is an intronless gene that spans 1376 bp. Open boxes 
represent 5’ and 3’ untranslated regions (UTR) and shaded boxes represent the coding 
sequences (CDS); the number of nucleotides is indicated below. (C) Alignment of the 
amino acid sequences of wild-type LDOC1 protein and the putative splice variant 
protein.  The wild-type mRNA encodes a protein composed of 146 amino acids. The 
splice variant mRNA, if translated, would yield a truncated protein of 44 amino acids 
that corresponds mainly to leucine zipper region of the wild-type LDOC1 protein. 
Identical residues are indicated by asterisks; the dashes indicate nucleotides that have 
been removed from the LDOC1S mRNA by alternative splicing. The leucine zipper 
domain (amino acids 5-40) in the wild-type protein, indicated by an open blue box, 
would be preserved in the splice variant. 
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Figure 5:  Expression of LDOC1 and LDOC1S assessed by RT-PCR. (A) 
Expression of LDOC1 and LDOC1S in cell lines, normal peripheral blood B cells, 
and CLL cells. Wild type LDOC1 (464 and 649 bp) and LDOC1S (165 bp) were 
detected in the MCF7 breast cancer cell line, two normal peripheral blood B cell (NBC) 
samples, and two unmutated CLL samples. Little or no LDOC1 or LDOC1S were 
detected in the Burkitt lymphoma cell line, GA10, the T-cell lymphoblastic lymphoma 
cell line, Jurkat, or two mutated CLL samples. (B) Expression of LDOC1 and LDOC1S 
in CLL cells. Wild type LDOC1 (464 and 649 bp) and LDOC1S (165 bp) were detected 
in the five additional unmutated CLL samples. Little or no LDOC1 or LDOC1S were 
detected in five additional mutated CLL samples. The amount of cDNA amplified for 
each sample was comparable, as shown by the beta-actin signal. 
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4.2.2 Total LDOC1 mRNA expression varies in NBC and B-cell subsets, CLL and 
 primary B-cell lymphoma samples, and cell lines by QRT-PCR assay 
 
 We assessed the expression of LDOC1 mRNA in unfractionated NBC samples 
and in NBC samples that had been enriched for naïve (CD27 ) or memory (CD27+) B 
cells. We also assessed its expression in 10 primary B-cell non-Hodgkin’s lymphoma 
samples, for which we had determined the IGHV somatic mutation status. The primary 
lymphoma samples included three follicular lymphoma samples (FL1, FL2, FL3, all 
mutated), four mantle cell lymphoma samples (MCL1, MCL2, and MCL4, mutated; 
MCL3 unmutated), one extranodal marginal zone B-cell lymphoma sample (MZL, 
unmutated), and two splenic marginal zone lymphoma samples (SMZL1, unmutated; 
SMZL2, mutated). For these experiments we used the commercially available QRT-
PCR assay that detects total LDOC1 mRNA; it does not distinguish between the 
isoforms. The results for unfractionated NBC and CLL samples, and lymphoma and 
carcinoma cell lines were consistent with the results obtained by the RT-PCR assay 
(Figure 6). For the fractionated NBC samples, the fraction enriched for naïve B cells 
expressed higher levels of LDOC1 mRNA than the fraction enriched for memory B cells.  
We found that LDOC1 mRNA was also expressed in primary B-cell lymphoma samples.  
Although the sample size is insufficiently large for a statistical analysis of individual 
lymphoma subtypes, there was a trend for the unmutated lymphoma samples, 
regardless of subtype, to express higher levels of LDOC1 mRNA than mutated 
samples. 
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Figure 6 
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Figure 6: Expression of total LDOC1 mRNA measured by QRT-PCR assay.  
LDOC1 levels are measured using a commercially-available TaqMan assay that does 
not distinguish between the LDOC1 and LDOC1S mRNA isoforms; mRNA quantity 
shown on the y-axis refers to total LDOC1 mRNA. LDOC1 expression was measured in 
carcinoma (HeLa, MCF7) and lymphoma (GA10, Jurkat) cell lines, unfractionated 
normal peripheral blood B cells (NBC4, NBC6), normal peripheral blood B cells 
enriched for memory B cells (NBC9M, NBC10M, NBC11M, NBC13M), normal 
peripheral blood B cells enriched for naïve B cells (NBC9N, NBC10N, NBC11N, 
NBC13N), and unmutated (U) or mutated (M) CLL and primary B-cell lymphoma 
samples, including follicular (FL), mantle cell (MCL), marginal zone (MZL), or splenic 
marginal zone (SMZL) lymphoma samples. Error bars represent the standard error of 
the ΔΔCt values. 
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4.2.3 LDOC1 and LDOC1S mRNA isoform expression by QRT-PCR assay 
 
Because the commercially available QRT-PCR assay fails to distinguish 
between the LDOC1 and LDOC1S mRNA isoforms, we were unable to assess the 
contribution of each isoform to the total LDOC1 mRNA levels that we observed using 
the RT-PCR and commercially available QRT-PCR assays. Thus, we designed QRT-
PCR assays that distinguish between the isoforms. (The primer and TaqMan probe 
components of each assay are described in Chapter 2.) 
 
In order to determine the assay specificity, that is, whether the TaqMan assay 
designed against the sequences of either LDOC1 or LDOC1S mRNA recognize their 
own sequence specifically, and discriminate efficiently between the two, we prepared 
synthetic templates that consist of the amplicons between the forward and reverse 
primer sequences, inclusive: the wild-type template is 5'-TGGTGCCCTACATCGAGAT 
GATAGCCCCATCCTAGGTGTTACCGGGCCTTCCTCG-3', and the splice variant 
template is 5'-TTCCAAGCACTTCCGAGTGACTATTCCTGGCGCAGCAGCAGCCGCA 
GCTGTTCCAT-3'.  We used 33,000 molecules of each primer as the cDNA template. 
Unlike cDNA obtained from samples, the primer templates allowed us to calculate more 
precisely the amount of input template in PCR reactions. We determined that the assay 
for the wild-type LDOC1 mRNA isoform recognizes the wild-type template with 14 x 106 
fold specificity compared to the splice variant template, as determined by RQ of 2-ΔCt = 
2-(Ct target - Ct homolog). The assay for LDOC1S mRNA isoform recognizes the splice variant 
template with 43 x 103 fold specificity compared to the wild-type template (Figure 7). 
Since a specificity of more than 30 x 103 fold is the standard used for the commercially 
available TaqMan assays (Dr. John Pfeifer, Life Sciences, personal communication), 
the assays we designed are highly specific. To account for the different assay 
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efficiencies, we used the data from all samples to fit a model expressing total LDOC1 
mRNA as a weighted linear combination of wild-type (WT) and splice variant (SV) 
contributions. For normalized mRNA levels, we found the optimal model to be Total = 
(0.67 x WT) + (0.24 x SV) (developed by Dr. Kevin R. Coombes). 
 
 We re-assessed the previously-tested samples described above using the 
isoform-specific TaqMan assays (Figure 8).  In general, for both benign and malignant 
cells, cells that expressed the wild-type LDOC1 mRNA also expressed the splice variant 
LDOC1S mRNA, but the wild-type isoform was predominant.
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Figure 7: Isoform-specific TaqMan assays are highly specific for their target 
transcript. Synthetic templates consist of the amplicons between the forward and 
reverse primer sequences were synthesized for LDOC1 and LDOC1S, corresponding to 
the sequences uniquely found in each isoform. TaqMan assays designed to specifically 
recognize their own templates were tested for specificity against each other’s template. 
Each arrow marks the threshold set for calculating the ΔCt values for the corresponding 
TaqMan assay against two different templates. The underlines indicate the templates, 
LDOC1 or LDOC1S. The specificities of the TaqMan assays are calculated as follows:  
ΔCt TaqLD1sv (Ct target LD1svTemplate-Ct homolog LD1wtTemplate)= 2
-(11.012-26.415) = 43,327 
ΔCt TaqLD1wt (Ct target LD1wtTemplate-Ct homolog LD1svTemplate)= 2
-(10.358-34.104) = 14,068,839 
TaqLD1: TaqMan assay for corresponding LDOC1 isoform (sv or wt); LD1wt: wild type 
LDOC1; LD1sv: splice variant of LDOC1 
Taq-LDOC1S
/LDOC1S
Taq-LDOC1S
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Figure 8 
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Figure 8:  Expression of wild-type LDOC1 and LDOC1S mRNA isoforms measured 
by QRT-PCR assay. We designed an assay that distinguishes between the isoforms. 
Gene expression was measured in carcinoma (HeLa, MCF7) and lymphoma (GA10, 
Jurkat) cell lines, unfractionated normal peripheral blood B cells (NBC4, NBC6), normal 
peripheral blood B cells enriched for memory B cells (NBC9M, NBC10M, NBC11M, 
NBC13M), normal peripheral blood B cells enriched for naïve B cells (NBC9N, 
NBC10N, NBC11N, NBC13N), and unmutated (U) or mutated (M) CLL and primary B-
cell lymphoma samples, including follicular lymphoma (FL), mantle cell lymphoma 
(MCL), marginal zone lymphoma (MZL), or splenic marginal zone lymphoma (SMZL) 
samples. Error bars represent the standard error of the ΔΔCt values. 
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3.3   Summary 
 
We evaluated LDOC1 mRNA expression in subsets of normal and malignant B 
cells, and in solid tumor cell lines. We discovered a shorter form of LDOC1, a novel 
splice variant that we called LDOC1S. If translated into protein, the splice variant would 
consist almost entirely of the leucine zipper region of the wild type protein, raising the 
possibility that it might interfere with the function of the wild type protein through 
dimerization between leucine zipper regions. The LDOC1S mRNA is co-expressed with 
wild type LDOC1 although its amount might vary between the cell types. However, we 
have not screened a sufficiently large number of samples to derive a statistically 
meaningful conclusion about the biological significance of LDOC1/LDOC1S ratio. 
 
 During our initial screen of 131 CLL samples for differential LDOC1 mRNA 
expression and subsequent survival analyses we used an MF-QRT-PCR assay. This 
assay uses an inventoried TaqMan assay that recognizes both LDOC1 and LDOC1S 
mRNAs.  After we discovered LDOC1S, we developed and tested isoform-specific 
TaqMan assays to determine the contribution of LDOC1S to the total LDOC1 mRNA 
measured by the MF-QRT-PCR assay. We found that the contribution of LDOC1S was 
very small. Had the expression of LDOC1S been significantly higher than that of wild 
type LDOC1 we would have screened a larger cohort of CLL patients to measure 
LDOC1S mRNA to evaluate its value as a biomarker of overall survival by itself.  
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CHAPTER 5. GENE EXPRESSION PROFILING FOLLOWING LDOC1 KNOCK-
DOWN IN HeLa CELLS IDENTIFIES POTENTIAL COORDINATELY-REGULATED 
BIOLOGIC PATHWAYS 
 
5.1    Introduction 
 
LDOC1 is a novel gene of unknown function. We hypothesized that global gene 
expression profiling would illuminate the biologic processes in which LDOC1 is involved. 
We chose HeLa cervical carcinoma cells, which highly express endogenous LDOC1 
protein, in order to elucidate changes in the transcriptome induced by LDOC1 protein 
knock-down. 
 
5.2    Results 
 
5.2.1 Optimization of LDOC1 protein knock-down 
 
 There are no previously published studies that demonstrate expression of 
endogenous LDOC1 protein using Western blot analysis. In order to demonstrate 
LDOC1 protein expression, we screened polyclonal and monoclonal LDOC1 antibodies 
from six commercial sources. Despite numerous experiments to optimize the conditions 
of the assay, we identified only one polyclonal antibody that gave reproducible results 
(although with some background) in a Western blot assay, which we used for our 
studies. 
 
 Before performing gene expression profiling, we first performed experiments to 
optimize HeLa cell transfection. As described in Materials and Methods, we transfected 
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HeLa cells with a siRNA pool that contains siRNAs directed against four different 
regions of the LDOC1 mRNA, including sequences within the LDOC1S mRNA. The 
transfected cells were harvested every 24 hours following transfection for 4 days, and 
LDOC1 protein expression assessed by Western blot analysis using a polyclonal 
antibody to LDOC1. The results of a representative experiment are shown in Figure 9.  
The cell confluence at 24 (data not shown), 48 (data not shown), 72, and 96 hours was 
60%, 95%, 100%, and >100%, respectively.  In untransfected cells (lanes 1, 5, and 9) 
LDOC1 protein was not observed until the cells reached 100% confluence, 72 hours 
after initiating the cultures, and was maximally expressed when the cells reached 
>100% confluence, 96 hours after initiating the cultures. By 72 hours after transfection, 
LDOC1 protein expression was substantially reduced in cells transfected with LDOC1 
siRNA, compared to untransfected cells, cells transfected with non-targeting siRNAs, or 
mock transfected cells. Western blot analysis performed using an antibody to beta-actin 
demonstrates that equivalent amounts of protein were added to each well. 
 
 In the same experiment, we also assessed the transfection efficiency by 
fluorescence microscopy 24 hours after transfection with fluorescently-labeled siRNA, 
siGLO Red. The efficiency was calculated by dividing the number of fluorescent cells by 
the total number of cells (mean of three different fields counted at 40X magnification), 
and was 92% (Figure 10). 
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Figure 9.  LDOC1 protein is knocked-down by specific LDOC1 siRNAs.  Cells were 
harvested at 72 or 96 hours after transfection and protein lysates (50 µg) were loaded 
into each well. Western blot analysis was performed using a polyclonal antibody to 
LDOC1 (upper panel) or a monoclonal antibody to beta actin (lower panel). The LDOC1 
protein is 17 kD (band is shown by arrow on upper panel). Abbreviations: UnTfx, 
untransfected; LD1siR, LDOC1 siRNA pool; Mock, mock transfection (all transfection 
reagents other than siRNAs); NTsiR, non-targeting siRNA #1. 
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Figure 10.  HeLa cells demonstrate high transfection efficiency by siRNA. 
HeLa cells transfected by fluorescently labeled siRNA, siGLO Red, were visualized 24 
hours after transfection under inverted light microscope (left) or fluorescent microscope 
(right) (20X magnification). 
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5.2.2. LDOC1 protein knock-down for microarray experiment 
 
The results of our optimization experiments indicated that LDOC1 protein was 
maximally knocked down 96 hours after transfection. Thus we chose to harvest cells at 
approximately this time point for subsequent gene expression profiling. Knock-down 
experiments were conducted in triplicate for each condition (untransfected, LDOC1 
siRNA transfected, non-targeting siRNA transfected, and mock transfected). At 93 
hours after transfection the cells had reached > 100% confluence. They were harvested 
and evaluated for cell number and viability (trypan blue exclusion), and cell cycle 
(propidium iodide staining followed by flow cytometry). In addition, protein and RNA 
were extracted to perform Western blot analysis (to confirm knock-down) and gene 
expression profiling. With respect to cell number, viability (data not shown), or cell cycle 
phase we found no difference between HeLa cells transfected with LDOC1 siRNAs and 
non-targeting siRNAs (Figure 11 A and B). We confirmed the high efficiency of LDOC1 
protein expression knock-down by Western blot analysis (Figure 12). 
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Figure 11.  Transfection with LDOC1 siRNA has no significant effect on cell 
number or cell cycle phase. (A) The cell number was evaluated by trypan blue 
exclusion and (B) cell cycle phases were evaluated by propidium iodide staining. 
 
 
 
 
 
 
Figure 12.  LDOC1 protein knock-down demonstrated by Western blot analysis.  
Protein was obtained 93 hours after transfection with siRNAs and 100 µg protein lysate 
was loaded into each well. LDOC1 protein was efficiently knocked down by specific 
LDOC1 siRNAs, but was unaffected by non-targeting siRNAs (upper panel). Antibody to 
beta-actin demonstrates that equivalent amounts of protein (100 µg per lane) were 
added to each well (lower panel). 
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5.2.3  Differentially expressed genes in siRNA-transfected HeLa cells 
 
We compared the gene expression profiles on RNA obtained from HeLa cells 
treated with LDOC1 siRNAs (LD) or non-targeting (NT) siRNAs. The array quality 
control analysis indicated that there was no significant evidence of outliers or abnormal 
hybridization patterns, and the overall array quality was good. The percentage of genes 
present for all the arrays ranged between 47-50% (expected between 30-60%), and the 
average, minimum, and maximum backgrounds were similar across the arrays. 
 
In order to identify differentially expressed genes between the LD and NT 
groups, we performed two-sample t-tests. Using false discovery rates (FDR) of 0.05, 
0.1, and 0.2, we identified 1, 4, and 107 differentially expressed genes, respectively.  
The fold value changes and p values of the 107 differentially expressed genes are 
presented in Table 3. In this table, fold changes indicate the ratio LD / NT. A positive 
fold change value indicates an increase in gene expression in LD compared to NT cells; 
a negative value indicates a decrease in gene expression in LD compared to NT cells. 
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Table 3. List of Differentially Expressed Genes in siRNA-transfected HeLa Cells 
 
Probe ID Gene Symbol Fold Change P value 
204454_at LDOC1 -5.24 0.000000144 
1556551_s_at SLC39A6 1.39 0.0000154 
214352_s_at KRAS 1.35 0.0000199 
205809_s_at WASL 1.28 0.0000209 
223266_at STRADB 1.07 0.0000385 
211949_s_at NOLC1 1.27 0.0000494 
221539_at EIF4EBP1 -1.48 0.0000536 
210537_s_at TADA2L 1.22 0.0000723 
212113_at LOC552889 1.23 0.0000877 
211212_s_at ORC5L 1.12 0.000088 
209169_at GPM6B 1.17 0.0000883 
212010_s_at CDV3 -1.27 0.0000927 
226264_at SUSD1 1.43 0.0000968 
202132_at WWTR1 1.20 0.000100038 
211503_s_at RAB14 1.20 0.000109765 
226020_s_at DAB1 /// OMA1 1.11 0.000139154 
219529_at CLIC3 1.09 0.000139573 
221059_s_at COTL1 -1.04 0.000141816 
207940_x_at CNR1 -1.10 0.000156992 
228801_at ORMDL1 1.18 0.000172399 
1561403_at SOHLH1 -1.24 0.000207897 
243349_at KIAA1324 -1.19 0.000210587 
1558378_a_at AHNAK2 1.43 0.000216582 
212775_at OBSL1 -1.07 0.000224804 
227639_at PIGK 1.09 0.000238186 
223592_s_at RNF135 1.13 0.000242704 
202412_s_at USP1 1.16 0.000252094 
205315_s_at SNTB2 1.20 0.000259242 
209920_at BMPR2 1.39 0.000261638 
243145_at --- 1.13 0.000273762 
226897_s_at ZC3H7A 1.22 0.000276911 
212808_at NFATC2IP 1.19 0.000278652 
206383_s_at G3BP2 1.13 0.00028099 
220144_s_at ANKRD5 -1.06 0.000288035 
217457_s_at RAP1GDS1 -1.07 0.00029406 
204078_at SC65 1.09 0.000300573 
215071_s_at HIST1H2AC 1.14 0.000302292 
224404_s_at FCRL5 -1.16 0.000305902 
241715_x_at ACPT -1.19 0.000307205 
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Probe ID Gene Symbol Fold Change P value 
1570130_at SPATS2 1.22 0.000310473 
232503_at --- -1.16 0.00031898 
221734_at PRRC1 1.09 0.000320222 
234724_x_at PCDHB18 -1.16 0.000322211 
1568640_at ASPRV1 -1.17 0.000324145 
236053_at LOC100128653 -1.12 0.000336741 
218576_s_at DUSP12 -1.08 0.00034521 
235266_at ATAD2 1.34 0.000351744 
212906_at GRAMD1B -1.10 0.000361663 
203491_s_at CEP57 1.20 0.000364253 
237837_at --- -1.10 0.000367065 
56256_at SIDT2 1.13 0.000369489 
1552307_a_at TTC39C 1.15 0.000370903 
218751_s_at FBXW7 1.14 0.000383996 
212451_at SECISBP2L 1.34 0.000385468 
232349_x_at DCAF6 1.18 0.000386059 
221520_s_at CDCA8 -1.09 0.00040314 
224471_s_at BTRC 1.04 0.000404038 
221396_at TAS2R7 -1.15 0.000412271 
226297_at --- 1.15 0.000412343 
219066_at PPCDC 1.14 0.000426938 
205226_at PDGFRL -1.39 0.000431297 
230155_x_at MSL1 -1.29 0.000436594 
1557896_at --- -1.22 0.00045447 
208018_s_at HCK -1.14 0.000459992 
223692_at NMNAT1 1.29 0.000462599 
239055_at FLJ43663 -1.22 0.00046488 
1556127_at DIP2A -1.15 0.00046601 
237740_at --- -1.13 0.000477778 
224190_x_at NOD1 1.14 0.000492446 
211587_x_at CHRNA3 -1.12 0.000511636 
241273_at --- 1.13 0.000514578 
208378_x_at FGF5 -1.24 0.000515624 
228936_at --- -1.03 0.000522271 
208297_s_at EVI5 1.28 0.000527051 
201959_s_at MYCBP2 1.12 0.00052857 
211801_x_at MFN1 1.15 0.000529138 
1562783_at LOC100128840 -1.28 0.000533645 
201562_s_at SORD 1.21 0.000534678 
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Probe ID Gene Symbol Fold Change P value 
229274_at GNAS 1.35 0.00053949 
214869_x_at GAPVD1 1.09 0.000546859 
227780_s_at ECSCR -1.31 0.00054713 
222975_s_at CSDE1 1.13 0.000548207 
211993_at WNK1 1.38 0.000549098 
1555057_at NDUFS4 1.17 0.000562023 
1569846_at --- -1.20 0.000573165 
239788_at --- 1.36 0.000587081 
226413_at LOC400027 1.10 0.000592997 
202658_at PEX11B -1.23 0.000599795 
200598_s_at HSP90B1 1.29 0.00061511 
229795_at --- 1.16 0.000629294 
203056_s_at PRDM2 1.40 0.000646625 
233261_at EBF1 1.32 0.000655267 
217988_at CCNB1IP1 1.11 0.00065986 
200841_s_at EPRS 1.44 0.00066462 
219658_at PTCD2 1.20 0.000665816 
200975_at PPT1 1.09 0.000671499 
222142_at CYLD 1.08 0.000681179 
1554372_at --- -1.19 0.000691453 
209254_at KLHDC10 1.25 0.000700331 
1558747_at SMCHD1 1.46 0.000718725 
1568957_x_at SRGAP2P1 1.11 0.000721806 
220653_at ZIM2 -1.25 0.000734443 
1568931_at --- -1.17 0.000743993 
212520_s_at SMARCA4 1.16 0.000753233 
229909_at B4GALNT3 1.08 0.000758928 
201479_at DKC1 -1.06 0.000761875 
226568_at FAM102B -1.06 0.000762703 
233827_s_at SUPT16H 1.36 0.000766658 
1556336_at 
LOC100131735 /// LOC100291994 /// 
RBMX /// RBMXL1 1.19 0.000766725 
235201_at --- 1.09 0.000784229 
239009_at KIAA0754 -1.26 0.000787619 
1570165_at --- -1.06 0.000789026 
212220_at PSME4 1.23 0.000801126 
235059_at RAB12 1.28 0.000809335 
217753_s_at RPS26 -1.06 0.000814191 
1553542_at CCDC125 1.26 0.000814995 
213286_at ZFR 1.31 0.000822981 
208209_s_at C4BPB -1.12 0.000837838 
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Probe ID Gene Symbol Fold Change P value 
202197_at MTMR3 1.14 0.000855254 
227087_at INPP4A 1.14 0.000856684 
236806_at --- 1.12 0.000868555 
 
 
 
5.2.4 Networks constructed from gene expression signature 
 
The differentially expressed genes listed in Table 3 belong to a variety of 
functional categories, including enzymes (BMPR2, BTRC, GNAS, KRAS, and RAB14), 
kinases (HCK, PDGFRL, and STRADB), and transcriptional regulators (FBXW7, 
PRDM2, and SMARCA4). To better understand the potential function of these genes 
and their relationships, we performed a network analysis using Ingenuity Pathways. A 
Core Analysis was performed using a 0.5 fold change value as the cut-off, querying only 
direct interactions between the 107 most significantly expressed genes. As shown in 
Figure 13, LDOC1 protein knock-down induced alterations in expression of a variety of 
genes that participate in wide range of biological processes, including regulation of 
gene expression, cellular function and maintenance, cancer, cell cycle, cellular growth 
and proliferation, cellular assembly and organization, cell death, and DNA replication, 
recombination and repair. To illustrate the construction of networks, Network # 2 is 
shown in Figure 14.  
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Figure 13. Ingenuity Pathways (IPA) Core Analysis reveals functional categories of differentially expressed genes. Of 16 
networks, only the most significant 6 networks are shown from the IPA analysis. Genes in bold-face type are focus molecules that 
we identified as differentially expressed (Table 3) and were uploaded into the Core Analysis by the investigator. Genes in non-
bold-face type are identified by the Ingenuity Knowledge Base as potential interaction partners and incorporated into networks. 
Red arrows indicate up-regulated molecules and green arrows indicate down-regulated molecules.   
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Figure 14. IPA Network 2 demonstrates potential interactions between genes that 
participate in cellular function and maintenance, cancer, and gastrointestinal 
disease. The shapes of gene symbols indicate their functional group. Solid lines 
indicate the direct interactions. Numerical values under the genes indicate mRNA fold 
changes in LDOC1 knocked-down cells compared to the NT control cells. Red indicates 
up-regulation and green indicates down-regulation of the mRNA of the respective gene. 
Genes are placed according to their location in the cell, i.e., extracellular space, plasma 
membrane, cytoplasm, or nucleus; genes for which the location is unknown are located  
on the right (“unknown”).
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Figure 14 
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5.3    Summary 
 
 We have successfully knocked-down LDOC1 protein in HeLa cells and 
performed gene expression profiling microarray analysis. This analysis revealed 107 
genes that are significantly differentially expressed between the cells transfected with 
LDOC1 siRNAs and non-targeting control siRNAs. These genes belong to a wide 
variety of functional groups. The list of differentially expressed genes were subjected to 
further analysis by performing a Core Analysis in Ingenuity Pathways, which allowed us 
to assign the differentially expressed genes into potential networks and visualize 
interactions between the differentially expressed genes within functional categories. The 
IPA analysis also revealed other potential interaction partners extracted from the 
Ingenuity Knowledge Base, in addition to the 107 genes identified by gene expression 
profiling experiment. Upon inspection of the networks, LDOC1 was found only in 
network 3. Relatively little is known about the function of LDOC1, and none of the 
molecules indicated as interaction partners of LDOC1 in this network have been shown 
experimentally to interact with LDOC1 in a mammalian system. Ingenuity Pathways 
constructs networks using all available published information, including bioinformatic 
analyses as well as experimental data, from the literature and databases. Thus, the 
results require validation in different tissue types and cellular contexts. 
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CHAPTER 6. INTERSECTION AND SUBSEQUENT VALIDATION OF 
COORDINATELY DIFFERENTIALLY EXPRESSED GENES IN HeLa CELLS AND 
CLL SAMPLES 
 
6.1 Introduction 
 
 Although gene expression profiling using microarrays allows the expression of a 
large number of genes to be assessed in a single experiment, the dynamic range of 
microarrays is relatively small (39, 40). Thus, genes identified as differentially 
expressed using microarrays should be validated using a more sensitive method, such 
as a QRT-PCR assay. We chose to validate genes that we identified as “coordinately 
regulated” in LDOC1 knock-down experiments in HeLa cells and in CLL samples.  We 
approached this problem in two ways. 
 
First, we compared two lists of differentially expressed genes generated by 
gene expression profiling microarray studies using Affymetrix arrays: (1) the list of 
genes differentially expressed between HeLa cells transfected with LDOC1 siRNAs (to 
knock-down LDOC1 expression) and non-targeting siRNAs, and (2) the list of genes 
differentially expressed with respect to LDOC1 mRNA expression in 30 CLL samples, 
obtained from a previous gene expression profiling microarray (34). Genes that were 
concordant for LDOC1 expression in both groups (HeLa and CLL) and whose function 
suggests that they might have relevance to the pathophysiology of CLL were to be 
evaluated by QRT-PCR assay. 
 
Second, we compared the two lists of differentially expressed genes generated 
by a MF-QRT-PCR assay for 43 candidate biomarkers of prognosis and 5 endogenous 
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control genes; 23 potential biomarkers have been reported previously (22) and 20 have 
been identified subsequently (Abruzzo LV, et al., manuscript submitted). We had 
previously assessed 76 CLL samples for expression of these 48 genes (including 
LDOC1). We performed the same MF-QRT-PCR assay on RNA obtained from 
transfected HeLa cells, as described above. 
 
6.2 Results 
 
 In the gene expression profiling experiments of HeLa cells using Affymetrix 
microarrays, the groups with “high” and “low” LDOC1 expression corresponded to cells 
that had been transfected with non-targeting siRNAs or LDOC1 SiRNAs, respectively.  
For the CLL samples, we reanalyzed the Affymetrix microarray raw data to allocate 
samples into groups with “high” and “low” LDOC1 mRNA expression. To achieve this, 
we first plotted LDOC1 mRNA expression levels for each sample to determine if there 
was a clear separation between samples with respect to LDOC1 mRNA expression 
(data not shown). Since this analysis failed to separate the samples into two distinct 
groups, we then plotted the Affymetrix expression data against the MF-QRT-PCR assay 
data collected previously in our laboratory (Figure 15). Based on this analysis, we 
concluded that the expression value of 7.6 on the log2 scale defined the best cut-off to 
separate the groups with LDOC1-high from LDOC1-low expression for Affymetrix data 
(shown as the black vertical line in the figure).  Differentially expressed genes between 
the LDOC1-high and LDOC1-low groups were determined using two sample t-tests. 
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Figure 15. Scatter plot comparing Affymetrix expression estimates against QRT-
PCR cycles defines the cut-off value for LDOC1 mRNA expression on Affymetrix 
arrays. Vertical lines indicate plausible cut-offs to separate LDOC1 mRNA expression 
into groups with high (right of the line) or low expression (left of the line), based on gene 
expression profiling Affymetrix data. The horizontal line separates LDOC1 mRNA 
expression into groups with high (below the line) or low expression (above the line) 
based on the MF-QRT-PCR data. The expression value of 7.6 on the log2 scale defined 
the best cut-off to separate the groups with LDOC1-high from LDOC1-low expression 
for Affymetrix data (shown as the black vertical line in the figure). PCR cycles = Mean 
ΔCt value based on the MF-QRT-PCR assay. The colored vertical lines indicate 
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alternative cutoff values to set the threshold for LDOC1 mRNA positivity measured by 
Affymetrix microarrays. 
 
 Next we compared the list of differentially expressed genes in CLL groups and 
HeLa cell groups with “high” and “low” LDOC1 expression. To narrow down the number 
of genes for validation, we selected concordantly expressed genes for which the p value 
in CLL and HeLa cells was < 0.05. The overlapping, differentially expressed genes are 
listed in Table 4. 
 
 
 
 
 
 
Table 4. Intersection of Differentially Expressed Genes Between CLL Samples 
and HeLa Cells. The CLL and HeLa p values refer to the significance of differential 
expression for that gene between LDOC1-high and LDOC1-low samples. The p 
combined value refers to the significance of gene expression change in the CLL and 
HeLa data when they are assessed simultaneously (Fisher’s exact test). For CLL cells 
the fold change values indicate the gene expression ratios of cases with high LDOC1 / 
low LDOC1; for HeLa cells the fold change values indicate the gene expression ratios of 
NT (high LDOC1) / LD (low LDOC1) cells. A positive value indicates an increase in 
gene expression; a negative value indicates a decrease in gene expression. Genes that 
are concordant show the same direction of change in CLL and HeLa samples. 
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AffyProbeID CLL P value CLL Fold Change HeLa P value HeLa Fold Change P Combined Concordant
204454_at 7.17E-11 1.653 1.44E-07 5.253 4.44E-16 Yes
217753_s_at 0.041280928 1.692 0.000814191 1.059 0.000379822 Yes
219024_at 0.011023732 0.745 0.003040962 0.736 0.000378917 Yes
201676_x_at 0.045090524 1.095 0.003547553 1.065 0.001558113 Yes
216222_s_at 0.019039041 0.881 0.003716954 0.548 0.000747027 Yes
208794_s_at 0.007330058 1.278 0.003920538 1.039 0.000329257 Yes
202944_at 0.041408589 0.875 0.004546794 0.883 0.001803235 Yes
48659_at 0.039342604 1.088 0.004699016 1.062 0.001773999 Yes
214452_at 3.93E-06 1.246 0.005504185 1.285 4.04E-07 Yes
205780_at 0.025449019 1.404 0.00559713 1.294 0.001403986 Yes
202678_at 0.005916584 1.192 0.005796159 1.080 0.000386849 Yes
200881_s_at 0.038323819 1.173 0.005981868 1.043 0.002150508 Yes
202600_s_at 0.019171443 0.649 0.00651801 0.803 0.001248037 Yes
205882_x_at 0.031204126 0.600 0.007339724 0.960 0.002148678 Yes
207031_at 0.044814279 0.926 0.007569084 0.878 0.003049066 Yes
213017_at 0.028034783 1.148 0.007682522 1.112 0.002033838 Yes
201524_x_at 0.041995482 1.149 0.010959026 1.066 0.003996535 Yes
214474_at 0.040485963 0.900 0.011108058 0.799 0.003915664 Yes
205469_s_at 0.00720127 1.260 0.013697712 1.193 0.001008507 Yes
200834_s_at 0.001163252 0.891 0.013924734 0.984 0.000194872 Yes
219411_at 0.027896294 1.107 0.014487817 1.241 0.003562117 Yes
216037_x_at 0.035630998 0.851 0.015468312 0.966 0.004686716 Yes
214136_at 0.003592161 0.899 0.01557867 0.835 0.000603868 Yes
213475_s_at 0.02024539 1.260 0.016225922 1.177 0.002963391 Yes
221579_s_at 0.001444114 1.166 0.017597489 1.075 0.000294286 Yes
204476_s_at 0.028243382 0.887 0.019006562 0.920 0.004578915 Yes
202350_s_at 0.001019723 0.924 0.019681207 0.871 0.000237146 Yes
212288_at 0.037095652 0.817 0.020512879 0.850 0.006225207 Yes
205280_at 0.038571401 0.949 0.02161636 0.863 0.00674485 Yes
216576_x_at 0.02880998 2.351 0.022686296 1.191 0.005446398 Yes
217835_x_at 0.041520332 1.118 0.023418633 1.034 0.007716366 Yes
200629_at 0.048204048 1.376 0.023496573 1.151 0.0088155 Yes
201798_s_at 0.006273149 0.902 0.023795307 0.930 0.001464315 Yes
201969_at 0.002178054 0.831 0.024250526 0.942 0.000573014 Yes
203767_s_at 0.019546553 0.954 0.024951662 0.924 0.004206952 Yes
204520_x_at 0.008232359 1.212 0.025267505 1.070 0.001971513 Yes
212744_at 0.049204322 0.930 0.025816847 0.843 0.009741301 Yes
201460_at 0.017569059 1.240 0.026763556 1.090 0.004073119 Yes
217418_x_at 0.040932625 0.707 0.030087019 0.936 0.009482234 Yes
203988_s_at 0.001676991 0.706 0.031232095 0.944 0.000568649 Yes
219128_at 0.014004784 0.843 0.032302933 0.959 0.003936273 Yes
212162_at 0.027990074 0.874 0.035029663 0.888 0.007772744 Yes
202669_s_at 0.025205352 0.909 0.035307156 0.829 0.007141121 Yes
200002_at 0.047204876 0.918 0.036583127 0.994 0.012712462 Yes
218571_s_at 0.023344055 1.136 0.04066558 1.035 0.007556221 Yes
218145_at 0.006111609 1.261 0.04164203 1.148 0.002360794 Yes
41858_at 0.017332907 0.930 0.041647164 0.975 0.00594361 Yes
78383_at 0.039295836 0.933 0.042754313 0.950 0.01241388 Yes
214949_at 0.034035352 1.280 0.044100829 1.089 0.011259854 Yes
205149_s_at 0.011042873 1.138 0.044118806 1.160 0.004202982 Yes
207149_at 0.030557123 0.930 0.04499689 0.843 0.010435128 Yes
216401_x_at 0.030799181 2.376 0.045939624 1.066 0.010697648 Yes
212350_at 0.026389523 1.256 0.047558577 1.052 0.0096395 Yes
210087_s_at 0.014594328 0.897 0.048712568 0.967 0.005864396 Yes
216699_s_at 0.030924111 1.268 0.049976695 1.105 0.011548508 Yes
 68 
Of the 51 statistically significantly differentially expressed genes between CLL 
and HeLa groups we performed a review of the literature to identify genes whose 
reported function suggested that they might contribute to the pathogenesis of CLL. We 
selected six for validation by QRT-PCR assay: NRIP1 (Hs00942766_s1, Applied 
Biosystems), DNAJA1 (Hs00266011_m1, Applied Biosystems), UBE2N 
(Hs00854751_s1, Applied Biosystems), ITGAL (Hs00158218_m1, Applied Biosystems), 
MAPKAPK2 (Hs00358962_m1, Applied Biosystems), and CLCN4 (Hs00156541_m1, 
Applied Biosystems). None of these genes were significantly differentially expressed 
between HeLa groups. Therefore, we did not proceed with validation in CLL samples. 
 
For the second approach, we assessed the HeLa groups (LD and NT) for the 
expression of 43 genes previously identified as potential biomarkers of prognosis in CLL 
(22). The format of the MF-QRT-PCR assay (microfluidics card) is presented in Figure 
16. The cDNA prepared from the same RNA used for the gene expression profiling 
microarray experiments was assessed. The microfluidics card contained eight ports; 
each port contains TaqMan assays that recognize the 48 different genes. The card was 
loaded with cDNA from triplicate cultures (three LD and three NT cultures, one sample 
from each culture in duplicate). The analysis identified three differentially expressed 
genes with a p value of less than 0.05: LDOC1, GFI1, and FOXO1 (Table 4). 
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Figure 16. Topographic view of the QRT-PCR assays for the genes printed on microfluidics card. The card includes 8 ports for 
loading 8 samples (on the left vertical side). Each sample is evaluated by QRT-PCR assay for 48 genes, extended to two rows. The 
genes 18S rRNA, GAPD, PGK1, GUSB, and ECE-1 served as endogenous controls. 
 
 
 
 
SLAMF1 OAS3 AICDA NT5C2 FGL2 TPST2 RIOK2 SKI CD86 P2RX1 18S SEPT10 ZBTB20 ZAP70 BANK1 TNFRSF8 WSB2 LPL COBLL1 ANXA2 FGFR1 GFI1 CRY1 LDOC1
BCL7A LASS6 NRIP1 CD14 NUDC MLXIP EGR3 FLNB TRIB2 ATF4 GZMK CCL5 BLNK ATRX;LOC728849GAPDH PGK1 ECE1 GUSB PRAME GLI1 AURKA SIRT1 CHEK1 FOXO1
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BCL7A LASS6 NRIP1 CD14 NUDC MLXIP EGR3 FLNB TRIB2 ATF4 GZMK CCL5 BLNK ATRX;LOC728849GAPDH PGK1 ECE1 GUSB PRAME GLI1 AURKA SIRT1 CHEK1 FOXO1
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Gene Fold Change T stats P value
LDOC1 6.14 24.75 0.00002
GFI1 2.79 8.37 0.00111
FOXO1 1.21 4.62 0.00986
TRIB2 1.34 2.42 0.07292
AURKA 1.11 2.32 0.08075
FGL2 0.28 -1.88 0.13397
NUDC 0.86 -1.85 0.13782
GLI1 0.72 -1.78 0.14972
AICDA 0.18 -1.73 0.15958
18S 0.77 -1.68 0.16744
LPL 1.07 1.64 0.17612
ATRX 1.98 1.57 0.19128
NT5C2 0.66 -1.50 0.20780
LASS6 1.30 1.46 0.21713
EGR3 1.75 1.37 0.24332
SIRT1 0.92 -1.33 0.25569
P2RX1 1.90 1.32 0.25755
CCL5 0.90 -1.31 0.25888
SLAMF1 0.15 -1.31 0.26063
ATF4 1.08 1.19 0.30134
GAPDH 1.14 1.11 0.33028
OAS3 1.33 1.03 0.36025
SEPT10 0.94 -0.98 0.38411
CD14 1.26 0.96 0.39318
PGK1 1.10 0.93 0.40309
RIOK2 0.82 -0.93 0.40489
SKI 0.85 -0.89 0.42531
ZAP70 1.07 0.75 0.49723
TNFRSF8 2.94 0.70 0.52318
CD86 2.44 0.61 0.57745
PRAME 1.06 0.59 0.58430
NRIP1 1.05 0.55 0.61246
MLXIP 0.81 -0.54 0.62055
CRY1 1.05 0.45 0.67826
BCL7A 0.91 -0.44 0.67990
GUSB 1.02 0.44 0.68507
CHEK1 1.05 0.40 0.71118
ANXA2 0.98 -0.36 0.73460
FLNB 1.02 0.33 0.75607
COBLL1 0.93 -0.32 0.76576
WSB2 1.02 0.26 0.80527
BANK1 0.98 -0.25 0.81418
GZMK 1.18 0.21 0.84117
TPST2 0.99 -0.15 0.88745
ECE1 1.01 0.14 0.89667
ZBTB20 1.01 0.10 0.92558
FGFR1 1.00 0.08 0.93820
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Table 5. The expression fold change values and significance of the genes in HeLa 
samples that are run on microfluidics cards. The T statistics show the direction of the 
expression change relative to LDOC1. A positive value indicates an increase in gene 
expression; a negative value indicates a decrease in gene expression. Genes that are 
concordant show the same direction of change in CLL and HeLa samples. Internal 
controls are 18S rRNA, GAPD, PGK1, GUSB, and ECE-1 genes. 
 
 Next, the CLL data that were previously collected using this card from 76 patients 
were grouped into LDOC1-high (27 patients) and LDOC1-low (49 patients) categories, 
and a two-group t-test was applied to determine the genes that were concordantly 
differentially expressed. We identified 30 differentially-expressed genes between the 
LDOC1-high and LDOC1-low CLL groups. When we compared this list of differentially 
expressed genes with the list obtained from our MF-QRT-PCR analysis of the HeLa 
samples, only LDOC1 and GFI1 showed concordant differential expression. 
 
 
6.3 Summary 
 
 In this section, we used two approaches to identify and subsequently validate 
genes with concordant LDOC1 expression in transfected HeLa cells and CLL samples. 
First, we compared the gene expression profiling data obtained using Affymetrix 
microarrays from the current HeLa experiment and a previously-performed CLL study in 
our laboratory (34). This approach identified 51 genes in common. We attempted to 
validate, by QRT-PCR assay, 6 genes from this list whose function suggested that they 
might contribute to oncogenesis: NRIP1, DNAJA1, UBE2N, ITGAL, MAPKAPK2, and 
CLCN4.  However, we were unable to validate any of these genes as differentially 
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expressed in HeLa cells that are transfected with LDOC1 siRNAs or non-targeting 
siRNAs.  Second, we compared the gene expression data for 43 candidate biomarkers 
of prognosis obtained by the MF-QRT-PCR assay from 76 CLL samples with the 
transfected HeLa cells. This analysis identified GFI1 (Growth Factor-Independence 1) as 
concordantly differentially expressed in both transfected HeLa cells and CLL samples. 
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CHAPTER 7.  DISCUSSION 
 
We previously identified LDOC1 as one of the most significantly differentially 
expressed genes in untreated CLL patients (22). This dissertation extends that study 
and addresses two major questions with respect to LDOC1: 1) Does LDOC1 mRNA 
expression correlate with other clinical parameters of prognosis and patient outcome, 
thus serve as a novel biomarker of survival in untreated CLL patients?, and  2) How 
does LDOC1 mRNA upregulation in unmutated CLL contribute to disease pathogenesis? 
 
To address the first question, we have expanded our knowledge of LDOC1 
mRNA expression in neoplastic and benign B cells (26). First, we have confirmed that 
LDOC1 mRNA is dramatically down-regulated in mutated CLL cases compared with 
unmutated cases in a larger patient cohort. It is possible that differences in LDOC1 
mRNA expression may be related to the enhanced ability of unmutated CLL cases to 
respond to proliferative stimuli and resist apoptosis compared to mutated CLL cases 
(41). Second, we show that high levels LDOC1 mRNA expression correlate with 
cytogenetic markers of poor prognosis and with high ZAP70 expression. Further, we 
demonstrate that LDOC1 mRNA expression is an excellent predictor of overall survival 
in previously-untreated CLL patients. Third, although the sample size is small, we find 
that LDOC1 mRNA expression is associated with unmutated IGHV somatic mutation 
status in other primary small B-cell lymphomas. Finally, we show that LDOC1 mRNA is 
expressed in normal peripheral blood B cells, and that its expression is higher in the 
naïve B cell than in the memory B cell fraction. A recent study that evaluated the gene 
expression profiles of human cord blood subpopulations identified LDOC1 mRNA as 
upregulated in the CD34+/CD133+ subpopulation, which contains hematopoietic stem 
cells and progenitor cells, compared to the more mature CD34 /CD133  subpopulation 
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(42). During the course of our study, we also discovered a novel splice variant, LDOC1S 
that is co-expressed with LDOC1 mRNA in normal B cells, CLL and primary lymphoma 
cells that we examined. These findings suggest that during the course of normal B-cell 
development LDOC1 mRNA levels may vary with the maturational stage and state of 
activation. An assessment of B cells obtained from different compartments and 
subjected to a variety of different stimuli is required to address this question. 
 
The presence or absence of somatic mutations in the IGHV genes separates 
CLL patients into two prognostic subsets (4, 43). Patients with unmutated IGHV genes 
have a median survival of 8 years compared to 25 years in patients with mutated IGHV 
genes. Gene expression profiling studies using microarrays demonstrated that the 
majority of unmutated CLL cases express ZAP70 mRNA (13). Subsequently, others 
showed that expression of ZAP70 protein correlates with mutational status and clinical 
outcome (14, 15). Recent studies suggest that ZAP70 protein expression may be a 
better predictor of time to treatment than IGHV somatic mutation status (16, 17). In our 
study, LDOC1 mRNA expression, IGHV somatic mutation status, and ZAP70 protein 
expression all predicted time to treatment in univariate analyses. In multivariate 
analyses, IGHV somatic mutation status performed marginally better than ZAP70 protein 
expression, which performed marginally better than LDOC1 mRNA expression (data not 
shown). However, our data indicate that expression of LDOC1 mRNA may predict 
overall survival better than either IGHV somatic mutation status or ZAP70 protein 
expression in previously untreated CLL patients. 
 
Chromosomal abnormalities, predominantly gains and losses, are strong 
independent predictors of prognosis in CLL. The most common abnormality is 
del(13)(q14), followed by del(11)(q22.3), the site of the ATM gene, trisomy 12, 
 75 
del(6)(6q21-q23), and del(17)(p13), the site of the TP53 gene (7-9). In the clinical setting 
these abnormalities are usually assessed using a panel of fluorescence in situ 
hybridization (FISH) probes. As the sole abnormality, del(13)(q14) is associated with a 
good prognosis.  In contrast, del(6)(q21-q23), del(11)(q22.3), del(17)(p13), del(13)(q14) 
with other abnormalities, and trisomy 12, are associated with more rapid disease 
progression and inferior survival. The abnormalities del(17)(p13) and del(11)(q22.3) are 
the most important independent cytogenetic markers of poor prognosis. Deletions in 
17p13, the site of the TP53 gene, are associated with resistance to therapy with purine 
analogs, such as fludarabine, and short survival (10-12). The IGHV somatic mutation 
status is associated with cytogenetic abnormalities detected by FISH analysis (44-46).  
For example, del(13)(q14) is found more often in mutated cases. Our results indicate 
that LDOC1 mRNA expression was associated with cytogenetic markers of prognosis. 
Cases that were LDOC1 mRNA negative were more likely to contain isolated 
del(13)(q14), while LDOC1 mRNA positive cases were more likely to demonstrate 
cytogenetic markers of poor prognosis. By SNP genotyping, no case showed loss of the 
LDOC1 gene; three mutated cases showed a gain in the LDOC1 copy number, but were 
negative for LDOC1 mRNA expression (data not shown). Further, we found no 
mutations in LDOC1 mRNA in the subset of CLL cases that we subjected to sequence 
analysis. Thus, the differences that we observed in levels of LDOC1 mRNA expression 
in mutated compared to unmutated CLL cases appear to result neither from copy 
number variation in the gene, nor mutations in the coding regions. 
 
If LDOC1 functions as a transcription factor, as hypothesized, then small 
alterations in its level of expression could profoundly affect other genes that it regulates, 
and could promote or inhibit tumor formation, depending upon the context. We are the 
first to report LDOC1S, a new splice variant of LDOC1. In cancer cells, altered 
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expression of mRNA splice variants may result either from the generation of a new 
mRNA variant or from a change in the tissue-specific ratio of normal mRNA isoforms.  
An example of the former is Ikaros, a zinc finger DNA binding protein that is critical for 
normal lymphocyte development network. Alternative splicing of Ikaros pre-mRNA yields 
eight different isoforms, each with a different DNA binding capacity and differential 
expression in normal and neoplastic lymphocytes (47). Alterations in the tissue-specific 
ratio of normal mRNA isoforms may also be associated with tumorigenesis. For 
example, Bcl-X, a member of the Bcl-2 family, undergoes alternative splicing to yield a 
long mRNA, Bcl-XL, which has anti-apoptotic activity, and a short form, Bcl-XS, which 
has pro-apoptotic activity. While Bcl-XL is primarily found in long-lived post-mitotic adult 
tissues such as brain, Bcl-XS is expressed abundantly in cells with high turnover, such 
as human lymphocytes. Loss of Bcl-XS expression is associated with shorter relapse-
free and overall survival in patients with acute myeloid leukemia (AML) (48), and a high 
ratio of Bcl-XL to Bcl-XS is associated with a poor prognosis in AML (49). Similarly, the 
interferon regulatory factor-1 (IRF-1) is a transcriptional activator that may function as a 
tumor suppressor gene.  IRF-1 has five splice variants that lack various combinations of 
exons 7, 8, and/or 9.  Although the variants are expressed in both normal and malignant 
cervical cells, they are found more abundantly in malignant cells. Most of the variants 
have been shown to inhibit the transcriptional activity of the wild type IRF-1 (50). 
 
If the LDOC1S mRNA splice variant were translated into protein, it would contain 
the leucine zipper motif of the wild-type protein, but would lack the proline-rich region, 
which contains an SH3-binding consensus sequence, and the acidic region in the C-
terminus. Mizutani and co-workers (51) constructed LDOC1 deletion mutants, and 
studied their localization and protein interactions following transfection into MDCK 
(Madine-Darby canine kidney) cells. They found that full-length LDOC1 localized 
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predominantly to the nucleus, whereas the N-terminal mutant protein (the leucine zipper 
region) localized to both the nucleus and cytoplasm. They also identified WAVE3, a 
predominantly cytoplasmic protein, as a binding partner of LDOC1. Co-expression of full-
length LDOC1 and WAVE3 proteins shifted the localization of LDOC1 from the nucleus 
to the cytoplasm, and was associated with decreased apoptosis. They concluded, 
therefore, that WAVE3 may inhibit the pro-apoptotic activity of LDOC1, either by 
sequestering it in the cytoplasm or by shuttling it from the nucleus to cytoplasm.  
Similarly, it is conceivable that LDOC1S binds to LDOC1 to form non-functional dimers 
that inhibit the pro-apoptotic and anti-proliferative activities of LDOC1, possibly by 
sequestering LDOC1 in the cytoplasm. Alternatively, within the nucleus LDOC1S could 
form nonfunctional dimers with LDOC1; these could compete with functional LDOC1 
dimers for DNA binding sites and inhibit its transcriptional regulatory activity. This 
scenario would be similar to the inhibitory actions displayed by members of the Id protein 
family, which contain helix-loop-helix dimerization domains but lack DNA binding 
domains (52). Id proteins act in a dominant negative fashion and control critical events in 
cell differentiation, proliferation and tumorigenesis.  It is also possible that LDOC1S may 
form non-functional heterodimers with other pro-apoptotic and/or anti-proliferative 
proteins. Either mechanism might contribute to the aggressive behavior of some tumor 
types that aberrantly express LDOC1 isoforms. 
 
The relatively high expression of LDOC1 mRNA isoforms in unmutated CLL 
cases compared to mutated cases, and their expression in a variety of tumor cell lines 
suggest that LDOC1 may contribute to aggressive clinical behavior. Because we are a 
tertiary care center, many of our patients received the diagnosis of CLL months to years 
before seeking care at our hospital. Thus, we do not know the LDOC1 mRNA expression 
status of their CLL cells at the time of initial diagnosis.  We also do not know if LDOC1 
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protein expression predicts overall survival in previously treated CLL patients. We have 
been unable to identify a sensitive and specific commercially-available antibody for use 
in either a Western blot or flow cytometry-based assay. However, QRT-PCR assays for 
a variety of different mRNA transcripts, such as BCR/ABL1 fusion transcripts, are now 
performed routinely in clinical molecular diagnostics laboratories (53). Thus, the lack of a 
robust antibody does not preclude the use of LDOC1 mRNA expression as a clinically 
relevant biomarker of prognosis. Whether LDOC1 mRNA expression is stable in cases 
that have undergone clonal evolution over the disease course or following therapeutic 
interventions, and if it is truly a better predictor of overall survival than either IGHV 
somatic mutation status or ZAP70 protein expression can only be answered by a larger 
longitudinal study. 
 
 After identifying LDOC1 as a novel biomarker to predict CLL prognosis, we next 
asked whether the differential mRNA expression had biologic relevance to CLL 
pathogenesis. Since very little is known about LDOC1, we performed global gene 
expression profiling to gain an understanding of the biologic processes in which LDOC1 
participates in general, and in B cell-related pathways, in particular. Gene expression 
profiling of HeLa cells revealed 107 genes that are significantly differentially expressed 
following LDOC1 protein knock-down. We further processed the 107 genes using 
Ingenuity Pathways to identify potential interaction networks. We found that the 
differentially expressed genes could be placed into a variety of pathways including 
regulation of gene expression, cellular function and maintenance, cancer, cell cycle, 
cellular growth and proliferation, cellular assembly and organization, cell death, and DNA 
replication, recombination and repair. When these networks were inspected, we 
identified several genes that participate in biologic processes in hematopoietic cells, 
such as EBF (Early B cell Factor), which is essential for initiation of early B cell 
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development from the lymphoid progenitor towards the pro-B cell stage (54, 55), and 
HCK (Hematopoietic Cell Kinase), a protein tyrosine kinase that is expressed 
predominantly in cells of lymphoid and myeloid lineage (56). However, the majority of 
these 107 differentially expressed genes are of unknown function in hematopoiesis or 
lymphomagenesis. 
 
 To identify and subsequently validate genes with concordant LDOC1 expression 
in transfected HeLa cells and CLL samples, we used two approaches. First, we 
compared the gene expression profiling data obtained using Affymetrix microarrays from 
the current HeLa experiment and a previously-performed CLL study in our laboratory 
(34). This approach identified 51 genes in common. We attempted to validate, by QRT-
PCR assay, 6 genes from this list whose function suggested that they might contribute to 
oncogenesis: NRIP1, DNAJA1, UBE2N, ITGAL, MAPKAPK2, and CLCN4. However, we 
were unable to validate any of these genes as differentially expressed in HeLa cells that 
are transfected with LDOC1 siRNAs or non-targeting siRNAs. Second, we compared the 
gene expression data for 43 candidate biomarkers of prognosis obtained by the MF-
QRT-PCR assay from 76 CLL samples with the transfected HeLa cells. This analysis 
identified GFI1 as concordantly differentially expressed in both transfected HeLa cells 
and CLL samples. We failed to detect GFI1 as differentially expressed in Affymetrix data 
acquired from HeLa and CLL cells grouped into LDOC1-high and LDOC1-low 
categories, possibly due to the smaller dynamic range of Affymetrix arrays compared to 
the QRT-PCR assay (three orders of magnitude of expression compared to seven, 
respectively) (20). 
 
 The gene Growth Factor-Independence 1 (GFI1) is a zinc finger transcription 
factor that was first identified in T-cell lymphoma cell lines as the target of Moloney 
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murine leukemia virus insertion, which resulted in enhanced cell growth.  Upon activation 
by viral insertion into its promoter, GFI1 conferred interleukin-2 (IL-2)-independent 
proliferation to a IL-2-dependent T-cell lymphoma cell line (57). Subsequently, it was 
shown that GFI1 is a transcription factor that contains a Snail/Gfi-1 (SNAG) domain, and 
regulates gene expression by repressing transcription through its repressor domain 
SNAG (58). The same study showed that GFI-1 overexpression inhibited cell death 
induced by IL-2 withdrawal in IL-2 dependent T-cell lymphoma cell line. This escape 
from cell death was strictly dependent on intact SNAG repression function (58). GFI1 
inhibits cell death of IL-2-dependent T cell lymphoma cell-lines in IL-2-deficient media by 
directly binding and repressing the promoter of Bax, a pro-apoptotic member of Bcl-2 
family.  The data also suggest that GFI1 represses the expression of another apoptosis 
promoting protein, Bak (59). 
 
 Evidence for the oncogenic potential of GFI1 comes from in vivo studies using 
transgenic mice. While a minority of mice transgenic for GFI1 alone developed T-cell 
lymphoma, the vast majority of mice transgenic for GFI1 in combination with PIM-1 or L-
MYC developed T-cell lymphomas (60). In vitro studies support the hypothesis that 
overexpression of GFI1 mediates lymphomagenesis. GFI1 has been shown to repress 
cell cycle inhibitory genes, CDKN1A and CDKN2b, which encode the proteins p21Cip1 
and p15INK4B, respectively (35, 61). However, the mechanism of this repression is 
independent of DNA-binding by GFI1. GFI1 and c-Myc are recruited to the promoters of 
these target genes by Miz-1, a transcription factor and interaction partner of c-Myc, to 
form a complex. This protein complex allows GFI1 and c-Myc to cooperate to repress 
transcription, without directly binding to the promoters of the target genes, and to 
contribute to proliferation. 
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 GFI1 is expressed by hematopoietic stem cells (HSC), common lymphoid 
progenitors, and granulocytic and monocytic progenitors (62). In vivo experiments using 
GFI1 knock-out mice have shown that GFI1 maintains the self-renewal capacity of the 
HSC by restricting their proliferative capacity (62, 63). Further, GFI1 also protects HSCs 
from stress-induced apoptosis (64).  In the hematopoietic system the gene expression 
patterns of LDOC1 and GFI1 are similar: both are highly expressed in HSCs and 
progenitor cells (42) and show higher expression in naïve peripheral blood B cells than 
memory B cells according to our (26).  Because both are highly expressed in HSCs, one 
can speculate that LDOC1 may cooperate with GFI1 in maintaining HSC renewal; this 
may have implications in maintenance of the leukemic stem cell as well. 
 
 Antigenic stimulation rapidly induces GFI1 expression in mature peripheral T 
cells, which suggests that GFI1 participates in T cell activation (65). Constitutive GFI1 
expression in Jurkat T lymphoma cells inhibits phorbol ester-induced G1 arrest by 
blocking the negative cell cycle regulator, p21, and also inhibits activation-induced cell 
death. It is not known if GFI1 expression is induced in benign or malignant B cells 
following activation with antigen or other stimuli, such as IL-4, CpG oligonucleotides, or 
IgM. Longo and co-workers have demonstrated that cells obtained from patients with an 
aggressive disease course (usually unmutated CLL cases) respond to in vitro stimulation 
by CpG oligonucleotides by proliferating. In contrast, CLL cells from patients with an 
indolent disease course (usually mutated CLL cases) respond to stimulation by 
undergoing apoptosis (41). Further, responsiveness to in vitro stimulation by CpG 
oligonucleotides may be a better predictor of prognosis than IGHV somatic mutation 
status (66). The findings that LDOC1 and GFI1 are expressed at significantly higher 
levels in unmutated CLL cases (22), which are more responsive to antigenic stimuli, than 
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in mutated cases, raise the possibility that both LDOC1 and GFI1 participate in signaling 
pathways that promote proliferation in CLL cells and contribute to its pathogenesis. 
 
A recent report demonstrates that the microRNA, miR155, is upregulated in 
normal B cells that have been stimulated with IgM/CD40 ligand or CpG oligonucleotides 
and in primary CLL cells, compared to unstimulated normal B cells. In human embryonic 
kidney 293 cells miR155 has been shown to down-regulate LDOC1 mRNA expression 
(67). Although we can find no published reports of GFI1 regulation by miR155, a 
bioinformatic query of the TargetScanHuman database for microRNA binding sites 
(www.targetscan.org, Release 5.1) for miR155 indicates that GFI1 has a putative binding 
site for this microRNA in its 3’UTR. Thus, LDOC1 and GFI1 expression may be 
coordinately regulated through miR155. 
 
 Our data raise the possibility that a potential interaction between GFI1 and 
LDOC1 contributes to CLL pathophysiology, possibly by enhancing responsiveness to 
antigenic stimulation. We have shown previously that high levels of mRNA expression of 
both GFI1 (22) and LDOC1 (22, 26) are associated with unmutated IGHV somatic 
mutation status, a marker of poor prognosis. In the current study, LDOC1 knock-down in 
HeLa cells resulted in down-regulation of GFI1 mRNA. It also resulted in decreased 
mRNA expression of two known GFI1 transcription targets, the pro-apoptotic gene BAX 
(59) and the cell cycle repressor gene CDKN1A (35) (p values, 0.065 and 0.008, 
respectively). Thus, it is possible that LDOC1 and GFI1 cooperate to inhibit apoptosis 
and promote cell proliferation in aggressive CLL. Interestingly, a recent report has shown 
that downregulation of Bax protein correlates with several parameters of poor prognosis 
in CLL patients, including higher Binet stage, shorter lymphocyte doubling time, higher 
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CD38 protein expression, and presence of chromosomal abnormalities in 11q and 17p 
and/or a mutation of the ATM or TP53 genes (68). 
 
It is conceivable that LDOC1 may directly regulate GFI1 gene expression by 
binding to its promoter and activating its transcription. Alternatively, LDOC1 may interact 
indirectly with GFI1 as part of the protein complex formed by Miz-1, GFI1 and c-Myc, as 
described above, to regulate transcription of GFI1 target genes, such as BAX and 
CDKN1A (35). Recent data suggest that c-Myc interacts with LDOC1 (69). Additional 
studies, such as chromatin immunoprecipitation and reporter assays, could be 
performed to determine if LDOC1 binds directly to the GFI1 promoter and controls its 
transcription. Similar studies could also be performed to determine if LDOC1 interacts 
with other proteins, for example, c-Myc, that regulate expression of GFI1 target genes 
and contribute to malignant behavior. 
 
 It has been shown that following stimulation with CpG oligonucleotides in vitro, 
CLL cells obtained from patients with an aggressive clinical course proliferate, whereas 
CLL cells obtained from patients with an indolent course undergo apoptosis (41). The 
same investigators also demonstrated that this proliferative response was generally 
associated with unmutated IGHV status, and predicted shorter time-to-treatment, 
progression free survival, and overall survival in a cohort of CLL patients. However, 
mutated cases that proliferated under these conditions had a poorer prognosis than 
mutated cases that underwent apoptosis (66). The finding that expression of both 
LDOC1 and GFI1 are upregulated in unmutated CLL cases raises the possibility that 
they interact to regulate the expression of the genes that enhance proliferation and/or 
inhibit apoptosis in CLL cells. Since selection of antigens through the B cell receptor has 
been implicated in the pathogenesis and progression of CLL (70-77), an in vitro study of 
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LDOC1 and GFI1 expression following stimulation, as well as established downstream 
pathways in CLL survival and proliferation, for example, Akt signaling (41), would be 
highly illuminating. 
 
 In summary, we have shown that LDOC1 mRNA expression is an excellent 
biomarker of overall survival in untreated CLL patients. Longitudinal studies in a larger 
cohort of CLL patients are warranted to determine the value of LDOC1 mRNA 
measurement as a clinical prognostic test. Our findings from gene expression profiling 
studies suggest that GFI1 might be one of the key genes with which LDOC1 interacts to 
contribute to CLL pathophysiology. 
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APPENDIX 
 
Supplemental Table 1. IGHV Somatic Mutation Status and Family, Expression of 
LDOC1 mRNA and ZAP70 Protein, and Genomic Abnormalities of the CLL cases 
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Abbreviations: M, mutated; U, unmutated; POS, positive; NEG, negative; NA, not 
available. 
* Total LDOC1 mRNA expression measured by MF-QRT-PCR assay 
† ZAP70 protein expression measured by immunohistochemistry or flow cytometry 
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‡ 
Biallelic loss 
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